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Abstract 
In this project there has been an attempt to study the coagulation cascade and anti-coagulants. 
The problem formulation of this project is ‘‘Can the shallowness of the dose-effect curve 
indicate Argatroban (a DTI) to be more effective in prevention of thrombosis than Unfractioned 
Heparin, where aPTT method is used on plasma samples in vitro?’’.  
The method used in the experiments was activated Partial Thromboplastin Time (aPTT). The 
normal assay consisted of addition of platelin, plasma and Ca2+ in equal volumes of 100 µl in a 
glass tube inside 37 °C water bath along with 10 µl of saline. The glass tube was tilted after the 
addition of Ca2+ and the time taken for the clot to appear in the tube after the addition of Ca2+ was 
measured and named as reference clotting time. The method was also applied by changing other 
variables such as the dilution Ca2+ in saline and dilution of plasma in saline while keeping the 
other variables constant. Moreover, the method was also applied to Heparin, where Heparin was 
added in dilutions of saline instead of the 10 µl saline. The same method as Heparin was applied 
on Argatroban in order to have the dose-effect curves of both anticoagulants for comparison.  
In the results related to the problem formulation, the dose-effect curve of Argatroban in vitro was 
steeper than the dose-effect curve of Heparin in vitro. Therefore the dose-effect curve of Heparin 
in vitro is actually, unlike what originally expected, shallower and more predictable than the dos-
effect curve of Argatroban in vitro. On the other hand, the literature showed a better dose-effect 
curve of Argatroban than Heparin. Therefore in conclusion the results of our experiments cannot 
be a good indicator for studying and comparing the effects of Argatroban to Heparin. 
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Glossary and abbreviations 
 
ACT: Activated Clotting Time, a coagulation test which is an alternative to aPTT when it is not 
useful. 
Actin: a globular protein found in the filaments of the muscle tissue aiding muscle contraction. 
Active site: the catalytic site of thrombin which is inhibited by all anticoagulants. 
Acute cerebral thrombosis: a thrombus formed in the brain which blocks the flow of blood 
through the vessels in the brain causing brain stroke. 
ADP: Adenosine Diphosphate, an ester of adenosine which for the purpose of energy storage is 
converted to ATP.   
AHG: Antihemophilic Globulin (table 8). 
Antithrombin III: a glycoprotein which inactivates several enzymes in the coagulation cascade. 
Arachidonic acid: a fatty acid found in animal fat which is an essential ingredient in the diet. 
arg-gly (R-G) bond: a peptide bond between the amino acids Arginine and glycine. 
arg-ile (R-I) bond: a peptide bond between the amino acids Arginine and Isoleucine. 
Arrhythmia: irregular heart beat rhythm.  
Arterial thrombosis: formation of a thrombus inside an artery causing the blockage of blood flow. 
Asymmetric carbons: a carbon which has links to four different groups of atoms. 
Atherosclerosis: a chronic disease caused by an irregular deposition of fatty materials in the 
inner wall of the arteries. 
Bioavailability: the extent to which a drug becomes available and effective in the circulation 
after administration. 
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Collagen: an insoluble fibrous protein in the connectives tissues of the animals. 
Da: a measurement unit of weight which is equal to the weight of a hydrogen atom 
DAG: Diacylglycerol, a second messenger in biochemical signaling; i.e. in platelets. 
Deep Venous Thrombosis: a formation of thrombus in a vein; most often in the leg. 
Dilute Russell Viper Venom Test: a laboratory coagulation test for the detection of lupus 
anticoagulants. 
Disaccharide: a carbohydrate group made of two sugar units. 
Disulfide bridge: a covalent bond between two thiol groups. 
Dose response curve: the curve of the relation of the clotting time to the dose of an anticoagulant. 
Endothelial cell: the layer of cells lining the inside of the blood vessels. 
Exosite 1: one of sites in the thrombin enzyme inhibited by the bivalent DTIs.  
Exosite 2: the site the fibrin bind in thrombin enzyme which is also inhibited by Heparin in 
soluble thrombin. 
Fibrinopeptides: either of the two peptide groups released by the fibrinogen activated by thrombin. 
Gla: Carboxyglutamic acid, produced by caboxylation of glutamic acid residue, provides high 
affinity to Ca2+ in the Vitamin-K affiliated clotting factors. 
Glucosamine: an amino sugar found in the linear structure of Heparin. 
Glutamine: one of the 20 amino acids in proteins. 
Glycoprotein: a protein containing oligosaccharide chains.  
Glycoprotein receptor: protein receptors found among other places on the surface of the platelets. 
Glycosaminoglycan: a long and high molecular weight polysaccharide with various repeated 
units of disaccharides. 
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GP Ib: an specific glycoprotein receptor on the surface of the platelets which facilitates their 
bindings to the endothelial cells through the vWF. 
GPIIb-GPIIIa: a specific glycoprotein receptor on the surface of the platelets which can 
facilitates their connection together through fibrinogen as well their binding to the endothelial 
cells through the vWF. 
G-protein: Guanine nucleotide binding protein is a protein in the second messenger cascades. 
Haematocrit: the ratio of the volume of the red blood cells to the entire volume of blood. 
Heparin Induced Thrombocytopenia: development of low number of platelets due to the 
administration of various forms of Heparins. 
HMWK: High Molecular Weight Kininogen (table 8). 
Hypercoagulability test: a clinical coagulation test which could verify the underlying cause of 
the coagulation disorders. 
Hyperlipidemia: an elevated abnormal level of fat inside the blood. 
Induronic acid: a type of carboxylic acid which is the major component of glycosaminoglycan. 
Inhibition constant: the dissociation constant of the complex of an enzyme and its inhibitor 
where a small number of the dissociation constant indicates a higher affinity and vice versa. 
Intravenous: inserting a liquid substance directly into a vein. 
In vitro: taking place in an artificial environment outside of the living body such as a test tube. 
In vivo: taking place inside of the living body. 
IP3: Inositol Triphosphate, a diacylglycerol involved in signal transduction pathways, including 
those of platelets by releasing the stored intracellular Ca2+. 
Isoform: a version of a protein which slightly differs from the original protein. 
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IU: International Unit is the unit for the measurement of the activity of enzymes (a unit for the 
measurement of the dose of Heparin). 
Lupus inhibitors or anticoagulants: a circulating anticoagulant which inhibits the activation of 
thrombin from prothrombin. 
Lysine: an alkaline amino acid. 
Macrophage: large white blood cells deriving from monocytes which in a nonspecific defense 
immune process destroy foreign and potential harmful matters. 
Myosin: a fibrous protein which together with Actin facilitates the contraction of muscles.  
Myosin light chain kinase: An enzyme activated by Ca2+ which phosphorylates the light chain 
of myosin and enables it to interact with actin in order to make the platelets motile. 
N-terminus: the terminal amino acid in a protein containing a free amine group. 
Oligosaccharide: short chain of sugar molecules. 
Pentasaccharide: a carbohydrate group made of five sugar units. 
Pharmacokinetics: the processes affecting the fate of a drug within the body such as its 
absorption, metabolism or excretion. 
Phospholipids a class of lipids forming the cell membrane present on the platelets’ surface 
taking part in major interactions of the platelets with the outside such as the platelet activation. 
PIP2: phosphatidylinositol-4,5-bisphosphate is hydrolyzed by the PLC in order to form IP3. 
Plasma half-life: the time it takes to reduce the concentration of a drug in plasma to half the 
initial concentration. 
Plasmin: an enzyme made in the blood by plasminogen which destroys the clot by attacking fibrin. 
Plasminogen: the inactive precursor of the plasmin enzyme present in the blood. 
Platelet aggregation: the joint clumping of several platelets leading to clot formation. 
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Platelet plug: a clump of platelets formed as a result of the aggregation and adhesion of several platelets. 
Platelin: an activator agent made of solid particles containing phospholipid reagents used in the aPTT test. 
PLC: Phspholipase C present on the surface of the platelets and activated by the thrombin 
receptor coupled to the g-protein takes part in the signal transduction pathway of platelets by 
hydrolyzing PIP2. 
Polysaccharide: a carbohydrate chain made of several monosaccharide units. 
Protein kinase C: an enzyme controlling the function of other proteins by phosphorylating the 
hydroxyl group of serine and threonine amino acid residues. In platelets PKC induces the 
degranulation othe platelets leading to the release of TXA2 which is a key player in the 
aggregation of platelets.  
Proteolytic enzyme: a protease is an enzyme which breaks down other proteins by hydrolyzing 
the peptide bonds of the forming amino acids in the polypeptide chain of that protein.  
Prothrombinase complex: the complex of the phospholipids on the surface of the platelets with 
the activated coagulation factor X and V along with Ca2+ which activates prothrombin to thrombin. 
PTA: Plasma Thromboplastin Antecedent (table 8). 
PTC: Plasma Thromboplastin Component (table 8). 
Purple toe syndrome: a rare and painful condition caused by Warfarin therapy which occurs 
when Cholesterol inside the cholesterol deposits of the vessels is released and moved through 
circulation (embolism) to be deposited in the feet.  
Renal clearance: elimination of a compound by the function of the kidneys. 
Reptilase test: a coagulation test adapted in the case of Heparin contamination in order to test 
the abnormalities or deficiencies in the fibrinogen. 
Saline: a solution containing sodium chloride salt. Isotonic saline has the same osmotic pressure as blood. 
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Stereoisomer: Molecules that have the same bond structure and the same atoms, but different 
three dimensional arrangements of their atoms. 
Subcutaneous: injection under the skin. 
Synthetic molecule: a molecule synthesized in the laboratory. 
Tenase complex: the complex of the phospholipids on the surface of the platelets with the 
activated coagulation factor IX and VII along with Ca2+ which activates cleaves and activates 
factor X. 
Therapeutic range: the dose range where a drug has the best activity. 
Thromboembolic disorder: a condition caused from the obstruction of a blood vessel by a 
thrombus which has dislodged from its original position. 
Thromboembolism: obstruction of a blood vessel by a thrombus which has dislodged from its 
original position. 
Tissue plasminogen activator: a protein found in the endothelial cells which facilitates the 
activation of plasmin by plasminogen.  
TXA2: Thromboxane A2 is a powerful vasoconstrictor which induces the aggregation of the platelets.  
Tyrosine: a polar amino acid. 
Vitamin K antagonists: a class of anticoagulants which function through the inhibition of the 
action of vitamin K which affiliates with several of the coagulation enzymes. 
Vitamin K epoxide reductase: an enzyme which reduces vitamin k after it is oxidized due to 
the caboxylation of glutamic acid. 
Vitronectin: an abundant glycoprotein that promotes cell adhesion and spreading found in serum 
and extracellular matrix. 
Warfarin necrosis: a condition developed by the deficiency of protein C after Warfarin therapy 
causing subcutaneous and skin necrosis (tissue death). 
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Introduction 
When the human body is physically damaged, arteries and/or veins may be damaged causing 
internal or external bleeding. To stop the loss of blood, different factors and agents existing in 
the blood play together in order for the blood to clot around the injured vessel. This process 
which prevents further loss of blood is known as haemostasis. Haemostasis is in fact a 
combination of several consecutive steps which commence instantaneously after the injury. The 
major mechanism is coagulation. Coagulation or clotting of blood does not however happen only 
after an injury to a blood vessel. Blood can also clot inside a blood vessel due to a number of 
factors, atherosclerosis being the most important, but also cancer, surgery etc (Prandoni et al. 
1996). The formation of a blood clot inside a blood vessel is known as thrombosis. Embolism 
occurs when thrombus in the blood vessel breaks free and moves through the circulatory system 
in order to block a blood vessel in another part of the body. 
The very general occurrence of thrombosis is in post surgery patients who develop thrombus as a 
result of their immobility due to pain or fatigue.  
According to a study conducted by Murtagh (2008), thrombus can occur in the deep veins of the 
leg in the patients who have just undergone a surgery, due to the immobility of these patients. 
Serious complication may arise if a thrombus breaks loose and end up in the brain or heart or 
lungs. Of other people who are at the risk of thrombosis, Murtagh mentions patients recovering 
from a coronary heart attack, patients with hardening of the arteries and patients with other heart 
problems such as the arrhythmia or leaking valve. 
In order to prevent thrombosis, pharmaceutical drugs known as anticoagulants or blood thinners 
are administered to the patients at risk. Warfarin is a widely used anticoagulant around the world. 
It is rather interesting to know that this drug was primarily sold in the market as a pesticide 
against rats and mice. Warfarin prompts the synthesis of defect coagulation factors (Elg et al. 
1998) and in this way disturbs the coagulation cascade.  
Heparin which usually derives from the intestine of the pigs is another common anticoagulant. Heparin 
exists in two forms, Unfractioned Heparin (UFH) and Low Molecular Weight Heparin (LMWH). 
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LMWH has the same effectiveness as UFH but is more convenient and cost-worthy than the 
unfractioned Heparin (Weitz and Bates 2005). Both UFH and LMWH function by forming a 
complex with the AT-III (Elg et al. 1998). The administration of Heparin in surgery patients is 
surveyed by measuring activated Partial Thromboplastin Time (aPTT) to ensure that optimal 
ranges of this drug is given to the patient.  
It is vital to determine the right dosage of anticoagulant in patients with coagulation problems since 
too much of it can cause bleeding and too little will be ineffective in prevention of thrombosis. 
Despite the commonality and usefulness of these anticoagulants, side effects can still occur. Besides 
haemorrhage or internal bleeding, Warfarin can cause allergic reaction, Warfarin necrosis and purple 
toe syndrome [1] while Heparin can cause Heparin Induced Thrombocytopenia (HIT) (Hassel 2008). 
Two new groups of anticoagulants known as the Direct Thrombin Inhibitors (DTIs) have also been 
developed. These anticoagulants, as it appears from their name, directly inhibit the thrombin 
enzyme in order to prevent thrombosis. Thrombin is an enzyme which acts at the second last step of 
the coagulation cascade by converting fibrinogen into fibrin. DTI anticoagulants have therefore 
advantages such as acting directly (and without intermediary steps) in comparison to the traditional 
anticoagulants such as Warfarin and Heparin. However there are also other advantages for the 
DTIs. DTIs have shallower dose response curves and wider therapeutic ranges compared to 
traditional blood thinner such as Warfarin (Elg et al. 1998). These advantages have therefore 
pushed scientists and pharmacologist to study and these anti-coagulants further. 
As it can be understood, coagulation can be inhibited at various steps of the cascade. The aPTT 
measures the very last process, cross linking of fibrin by thromboplastin, which can only occur if 
fibrin is first formed. This assay is therefore a general assay valuable to estimated effects on the 
coagulation process. 
The main aim of this project is to investigate about the coagulation process and the role of anti-
coagulants such Heparin and the DTIs in the prevention of thrombosis. This is done by studying 
relevant literature and by a lab experiment where we demonstrate the effect of anticoagulants on 
the coagulation process estimated by the aPTT. 
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Problem formulation and analysis 
 
Problem motivation 
In the current advanced world of medicine, the problems associated with the coagulation in the 
human body have been somewhat considered as an Achilles heel. These problems can include 
the lack of the necessary coagulation factors causing bleeding. On the other hand thrombosis is 
also caused by an irregular clotting in the blood which can result in embolism. Developing new 
and effective anticoagulants or blood thinner has therefore always been a challenge for 
pharmacologists. The development of the Direct Thrombin Inhibitors can potentially be 
considered as a victory in the fields of medicine and pharmacology.  
In this project we intend to firstly study the important mechanism of coagulation in the human 
body. Studying the mechanism of anticoagulants such as Heparin and the DTIs is the second aim 
of this project. The essence and the core of this project; however, is to compare the effectiveness 
and the quality of the Direct Thrombin Inhibitors with Heparin. 
 
Problem formulation 
Can the shallowness of the dose-effect curve indicate Argatroban (a DTI) to be more effective in 
prevention of thrombosis than Unfractioned Heparin, where aPTT method is used on plasma 
samples in vitro? 
 
Strategy 
In order to investigate and hopefully answer this problem a clear strategy has been planned. As 
mentioned before, studying the coagulation mechanism is one of the goals of this project. 
Therefore a part of the theory would be used to clarify major and essential points about the 
coagulation mechanism of blood in the human body. Providing this part would thereby enable us 
to comprehend the connections to the anti-coagulation mechanism of anticoagulants.  
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The second part of the theory would be used for anticoagulants. In this part there would be an 
explanation of the history, nature, mechanism and other important information of each 
anticoagulant. The anticoagulants described are Heparin and the DTI’s such as Hirudin, 
Bivalirudin and Argatroban. The final part of the theory is to present the method which is used in 
the experiments. This method is activated Partial Thromboplastin Time or aPTT. There would be 
an attempt to explain the necessary points about this method.  
In the experimental part of the project, we intend to not only answer the problem formulation but 
also try to test the other variables and factors involved in the coagulation cascade. Of these 
factors, Ca2+ is an important component of the coagulation cascade. Therefore experiments using 
aPTT method would be done to study the effect of different concentrations of this ion on the 
clotting time. The major part of the experiments is to test the dose effect of Unfractioned Heparin 
and Argatroban (a DTI). The acquired data would be presented in graphs.  
Afterwards, there would be a thorough and detailed discussion of the experiment results. The 
discussion of results would be accompanied with comparisons to the relevant materials adopted 
from the literature. In the discussion of the main results of the experiments, where the dose-effect 
curves of Heparin is compared to Argatroban, shallowness of the curve would be considered as 
an advantageous criterion for an anticoagulant. This is because in this curve where the clotting 
time is plotted against the dosage of the anticoagulant, the anticoagulant which has more 
predictable response to dosage change is more effective and useful (discussion). 
The experiments would be carried out at the clinical biochemistry laboratory of the Roskilde 
Hospital. It is also necessary to mention the following about the report: 
• The references for the internet links are presented in square brackets. 
• The terms and abbreviations that are explained in the glossary section are written in the 
italic format.  
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Theory 
Coagulation 
 
Overview 
When a blood vessel in the human body is damaged, a process consisting of a series of complex 
reactions should occur in order to stop the bleeding and repair the damaged site. This series of 
reactions are commonly known as haemostasis. Haemostasis is generally divided into three 
different steps and ends with its major component known as coagulation. These steps include: 
1. Vasoconstriction 
2. Platelet plug construction 
3. Coagulation 
These three steps would be further explained in the following.  
 
Vasoconstriction and platelet activation 
Following the damage to a blood vessel, the muscular wall of the damaged vessel starts to 
contract as an immediate reflex to the damage. This process called vasoconstriction stops further 
blood loss by narrowing the damaged blood vessel. 
When vasoconstriction has successfully prevented the flow of blood to the site of injury the 
second step of haemostasis is initiated by the activation of the platelets.  
As it is seen below (figure 1), the platelets which are present in the blood, circulating all over of 
the body, have to be able to connect to the surface of the injured vessel and to each other in order 
to form the platelet plug. This connection occurs when the collagen in the membrane of the 
endothelial cell attaches the platelet to itself. This link is mediated by the von Willebrand factor 
(vWF) acting like a bridge between the collagen fibrils and the specific receptor on the surface of 
the platelets. The specific receptor is a glycoprotein complex which as presented in the figure has 
the abbreviation of GP Ib.  
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The connection of the platelets to the endothelial cells is followed by the attachment of thrombin 
to the thrombin receptor on the surface of the platelet. The connection of thrombin to the platelet 
initiates the activation of platelets with the involvement of a series of reactions. 
A more elaborate illustration of these reactions is presented (figure 3) and discussed in the next 
paragraphs. 
 
Figure 1: platelet’s interaction with the outside and the role of it receptors (Besa et al. 1992) 
As presented in the figure, several of the receptors on the membrane of the platelets bind with outside factors or cells upon 
activation, leading to the adhesion and aggregation of the platelets. GP Ib is one of these receptors which binds the platelet to the 
endothelial cells with von Willebrand factor (vWF) mediating this adhesion. vWF does also bind to the GPIIb-IIIa receptors of 
the platelets which is not shown in the figure. Platelets also interact with each other by a mediation of fibrinogen bring bound to 
the GPIIb-IIIa receptors of each platelet. The thrombin and ADP receptor are also presented to show how ADP stimulates the 
arachidonic acid pathway (AA) and how the release of Thromboxane A2 (TXA2) leads to further aggregation of platelets.  
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Figure 2: a platelet’s internal reactions involved in its activation and aggregation [2]  
As presented in the figure, adhesion of collagen to PLC receptor on the platelet initiates the activation of Protein kinase C (PKC) 
through DAG. PKC regulates many platelet responses by its direct role in the granule secretion. The release ADP which is a 
content of platelet’s granule and its consequent role in the production of TXA2, being an important agent in the aggregation of the 
platelets, shows how PKC is also an indirect player in the aggregation of platelets. Moreover, the rise of [Ca2+], as a result of 
collagen’s adhesion to the PLC receptor of platelets, will also produce TXA2 and help the aggregation of platelets. 
 
As presented above (figure 2), the thrombin receptor on the platelets coupled to a G-protein 
activates PLC. PLC increases the concentration of Ca2+ by hydrolyzing PIP2 leading to the 
formation of IP3 which then prompts the release of Ca2+. PLC will also produce DAG that will 
also activate protein kinase C.   
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Protein kinase C initiates a signal transduction pathway by phosphorylating and activating a 
specific Dalton platelet protein which helps in releasing the contents of the platelets granule at 
the time of aggregation. One of the important contents of the platelets granule is ADP. ADP is a 
key player in providing a linkage between platelets and their ultimate aggregation. ADP does this 
by modifying the platelet membranes resulting in the exposure of the platelet glycoprotein 
receptor complex GPIIb-GPIIIa which acts as a receptor for fibrinogen. Fibrinogen gathers and 
aggregates the platelets together resulting in the platelet plug. 
The Ca2+ on the other hand can also help in the release of the granule content, but its significant 
role is in the release of TXA2. TXA2 is produced when the intracellular Ca2+ activates the 
phospholipids on the cell membrane and releases arachidonic acid. The release of arachidonic 
acid will therefore produce TXA2. 
TXA2 is a powerful vasoconstrictor that functions through the PLC pathway. Its primary role is 
to act as mediatory between platelets during platelets aggregation leading to the ultimate 
formation of the platelet plug. Apart from being a powerful vasoconstrictor and a key player in 
gathering of the platelets it does also have a role in the granule secretion of the platelets.  
Myosin light chain kinase (MLCK) is another enzyme activated as a result of the intracellular 
Ca2+ being released. MLCK in its activated form can phosphorylates the light chain of myosin 
and therefore enable it to interact with actin. Myosin and actin filaments both exist on the 
platelets and the interaction of these two proteins results in the contractions of platelets during 
their aggregation together and help to tighten the plug [3].  
All the above mechanisms allow the platelets on the damaged blood vessel to be activated in 
order to aggregate and form a platelet plug but it is also important to mention that the 
phospholipids on the activated platelet surface have an important role in the activation of the 
coagulation cascade. 
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The coagulation cascade 
 
Coagulation factors are indicated by Roman numbers where 
coagulation factors are generally composed of
Factors VIII and V are glycoproteins, and Factor XIII is a transglutaminase. Serine proteases
at specific sites. The serine protease coagulation factors circulate as inactive zymogens
pathways of the coagulation cascade consist of a series of reactions
factor are activated to become the active units
cross-linked fibrin at the end of the cascade.
The coagulation cascade is primarily divided into t
common pathway and in the activation of factor X, thrombin and fibrin.
 
As it could be seen by looking at the coagulation cascade
cascade to be initiated, the intrinsic and the extrinsic. These two pathways lead into a common 
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Figure 3: the coagulation cascade [4]
  
a lowercase added to indicate the active form of a factor
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 (inactive enzyme precursor)
 where a zymogen of a serine protease and its glycoprot
 which then catalyze the next reaction in the cascade. This ultimately leads to the 
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pathway in order for the clotting to occur. There are several biological and biochemical proteins or 
molecules which interfere in the cascade and they are usually classified by Roman number systems 
but in order to describe the processes of the cascade the biochemical or the trivial names for these 
factors would be used. The description of the cascade is assisted by looking at figure 3. 
The mechanism of coagulation following the activation of the platelets, by means of intrinsic and 
extrinsic pathways, is presented in figure 3. The general principle is that all factors that are present 
in inactive forms are then activated by the preceding step, most often via a proteolytic reaction. 
The intrinsic pathway also known as the contact activation pathway is triggered when the blood 
comes in contact with the exposed negatively charge surface. The extrinsic pathway on the other 
hand is triggered when tissue factor is exposed as a result of a vascular injury. Tissue factor is a 
glycoprotein on the surface of the subendothelial cells which is able to bind with phospholipids 
on the surface of the platelets.  
 The two pathways finally converge at a point where the Stuart-Prower factor (factor X) activates 
its conjugate factor Xa which then by hydrolyzing prothrombin activates it into thrombin. 
Thrombin does in one hand act as a regulatory factor which would further be discussed but in 
this context it converts fibrinogen to fibrin and also activates fibrin stabilizing factor (FSF or 
factor XIII) into its conjugate factor XIIIa. As it appears from its name FSF cross-links with the 
fibrin polymers in order to solidify the clot.  
As it could be noticed, the blood clotting cascade involves several consecutive reactions such as 
activation or conversion of different factors. These factors have been briefly presented (tables 7 
and 8, appendices) with a summary of their function. It is also necessary to say that the trivial 
names of the factors have been taken from these tables. The coagulation pathways are going to 
be more thoroughly studied in the following paragraphs. 
 
The intrinsic clotting cascade 
The intrinsic pathway which is also known as the contact activation pathway has much less 
importance in the haemostasis mechanism under normal physiological circumstances. Irregular 
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conditions such as hyperlipidimic or bacterial infiltration can initiate the activation of thrombosis 
by the intrinsic pathway. 
Hageman factor (factor XII) needs to bind with a negative charged surface which is exposed as a 
result of injury. At the same time the contact activation cofactor (HMWK) and the Fletcher factor 
(prekallikrein) form a complex which also interacts with the exposed surface.  
In hyperlipidemia, the negative surfaces of the phospholipids of the circulating lipoproteins in 
the blood offer binding sites for the Hageman factor.  
As a result of the interaction with the negative charged surface, the Fletcher factor is converted 
into its conjugate form (prekallikrein to kalikrein) which in turns converts the Hageman factor 
into its activated form (factor XII to factor XIIa). The activated Hageman factor can also covert 
prekallikrein to kalikrein and therefore trigger the cascade even further. 
The activated form of the Hageman factor is in fact the result of the cleavage of the original 
factor into two residues, where one of the residues is the active site of the Hageman factor or the 
activated form of this factor. These two residues can combine to each other again and again even 
after their cleavage and therefore trigger the cascade even further by a reciprocal behavior. 
Activated Hageman factor would also convert the PTA factor into its activated form (factor XI to 
factor XIa). HMWK also facilitates this conversion by binding to the PTA factor.  
Activated PTA factor does in turn convert the PTC factor into its activated form (factor IX to 
factor IXa). 
The presence of Ca2+ is necessary in order to proceed efficiently in both of the former 
conversions. Ca2+ binds with vitamin-K dependant gla residues present on these factors and thus 
facilitate their conversion. Several others of the factors (X, II and VII) in the coagulation cascade 
make use of Ca2+ in the same way.  
Active PTC factor converts Stuart-Prower factor into its activated form (factor X to Xa) by 
cleaving it at an internal arg-ile (R-I) bond. The activation of Stuart-Prower factor, which in fact is 
the initial stage of the common pathway, is however a bit more complicated since the activated 
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platelets have to assemble a tenase complex by binding Ca2+, activated AHG and PTC and the 
Stuart-Prower factor on their surface first. Phospholipids present on the surface of the activated 
platelets allow the formation of this tenase complex by interacting with the components.  
AHG factor is activated (factor VIII to VIIIa) by the presence of small amounts of thrombin. 
This factor facilitates the formation of the tenase complex by acting as a receptor for the Stuart-
prower and the activated PTC factors. Therefore AHG is in fact a cofactor in the coagulation 
cascade. An increase in the concentration of Thrombin enables this factor to inactivate the 
activated AHG factor as a reverse mechanism in order to control the formation of the tenase 
complex and the extent of the coagulation cascade. 
 
The extrinsic clotting cascade 
The extrinsic pathway, also known as the tissue factor pathway is triggered by the release of 
tissue factor, TF (factor III) as a result of trauma.  
TF acts as a cofactor in the activation of the Stuart-Prower being catalyzed by the activated 
Proconvertin factor (factor VIIa). Proconvertin factor cleaves the Stuart-Prower factor at an 
internal R-I bond and thus activate this factor (just like the intrinsic pathway). 
Proconvertin factor can itself be activated either by the activated Stuart- Prower factor or through 
the action of thrombin. Therefore the activated Stuart-Prower factor connects the intrinsic and 
the extrinsic pathways by being able to activate Proconvertin. 
On the other hand the TF-Proconvertin complex is also capable of activating the PTC factor in 
the extrinsic pathway and thus therefore creating yet another link between the two pathways.  
 
Activation of prothrombin to Thrombin 
The extrinsic and intrinsic pathways converge at the activation of the Stuart-Prower factor. The 
Stuart-Prower factor will then activate prothrombin to thrombin which in turn converts 
fibrinogen to fibrin. 
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The activation of thrombin from prothrombin happens at the surface of the activated platelets and 
demands the creation of the prothrombinase complex. The complex is made very similar to the 
formation of the tenase complex, where in this case the activated Stuart-Prower and Proaccelerin 
factors, Ca2+ have to bind on the surface of the activated platelets and the phospholipids present 
on the surface of the activated platelets will interact with the components and take part in the 
formation of the prothrombinase complex. 
Activated Proaccelerin factor (factor Va) acts as cofactor in the formation much similar to the 
role of the AHG factor in the formation of the tenase complex. This factor takes part in the 
formation of the complex by binding to the specific receptors (phospholipids) on the activated 
platelets and forming a complex with the activated Stuart-Prower factor and prothrombin.  
However the similarity is even further extended, because Proaccelerin also becomes activated by 
small amounts of thrombin. And just like AHG factor the activated Proaccelerin factor becomes 
inactivated by an increase in the concentration of thrombin. 
In the prothrombinase complex, prothrombin is cleft by the activated Stuart-Prower factor at two 
different sites. This cleavage produces a two chain active thrombin molecule which has an A and 
B chain held together by a single disulfide bridge.  
 
Thrombin as a regulatory factor 
As mentioned before Thrombin regulates the activation or inactivation of the AHG and 
Proaccelerin factors in the coagulation cascade. The mechanism by which thrombin 
accomplishes this task is to combine itself with thrombomodulin which is a protein present on 
the endothelial surfaces. This combination of thrombin and thrombomodulin results in a complex 
which activates protein C. Protein C along with the Protein which is another cofactor in the 
coagulation cascade degrade the two activated factors of AHG and Proaccelerin and therefore 
inactivate them. 
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Activation of Fibrinogen to Fibrin 
The following is adapted from the Medical Biochemistry Page [3]. 
Fibrinogen or factor I is made of 3 pairs of polypeptides ([Aα][Bβ][γ])2. These six chains are 
linked covalently by disulfide bridges near their N-terminus. The fibrinopeptides A and B exist 
respectively on the A and B portion of the Aα and Bβ chains. 
The fibrinopeptide regions of fibrinogen contain several glutamate residues spreading a high 
negative charge that helps fibrinogen to be dissolved in plasma. The activated thrombin which is 
a serine protease can hydrolyze the fibrinogen at four arg-gly (R-G) bonds between A and B 
portions of the fibrinogen and the fibrinopeptides regions.  
The release of the fibrinopeptides initiated by the thrombin forms fibrin monomers with the 
subunit structure (αβγ)2. These monomers spontaneously aggregate in an orderly assemblage 
order to form a weak fibrin clot. Factor XIIIa converted from factor XIII by thrombin which is a 
highly specific transglutaminase can cross-link itself with the fibrin by a covalent bond between 
the amide nitrogen of glutamines in its molecule and the ε-amino group of lysines in the fibrin 
monomers.  
 
Dissolution of clots 
The process of the dissolution of clots also known as fibrinolysis is a crucial mechanism in order 
to dissolve the formed clots which could potentially block the flow of blood or move around the 
circulatory system. The process is carried out by plasmin which is a strong proteolytic enzyme. 
Plasmin circulates in the blood in the form of its inactive proenzyme plasminogen. Plasminogen 
is activated by the tissue plasminogen activator (tPA). Plasminogen and the tPA are bound to 
fibrin in the formation of clot. The tPA would convert plasminogen into the plasmin which then 
breaks the fibrin monomers down by attacking it at 50 different sites. The fibrin monomers 
would therefore be significantly smaller and have less clotting capability. Plasminogen and 
plasmin are then inactivated by binding with their specific inhibitors.  
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Anticoagulants 
Anticoagulants, blood thinners – are pharmaceutical drugs that inhibit blood coagulation mainly 
by disabling one or more of the coagulation factors. Anti-coagulants are divided into three 
different main groups:  
1. Vitamin K antagonists 
2. Heparin (and its derivatives) 
3. Direct Thrombin Inhibitors 
Each of the groups of anticoagulants prevents coagulation in a different process. Vitamin K 
antagonists act by inhibiting Vitamin K epoxide reductase which reduces Vitamin K that has a key 
role in the activation of several factors in the coagulation cascade. Heparin works by activating 
antithrombin III which prevents thrombin from clotting blood. Direct Thrombin Inhibitors inhibit 
the thrombin enzyme, thus inactivating the cascade in its second final stage which is the formation 
of fibrins (the final stage being the cross linking of fibrin). The mechanism of the anticoagulants, 
related to the problem formulation of this project, is discussed in the following. 
 
Heparin 
Heparin is one of the widely used traditional anticoagulants (apart from Warfarin).  
Heparin exists in two forms: 
- Low Molecular Weight Heparin (LMWH) 
- Unfractioned Heparin (UFH) 
The differences between these two forms of Heparin and the necessary information on each one 
would be presented in the following sections. 
It has been determined that Unfractioned Heparin has a molecular weights ranging from 5000 – 30000 
Da while the average weight of LMWH is between 1000 – 10000 Daltons (Rydberg et al.1999). 
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Low Molecular Weight Heparin has more or less the same effectiveness of Heparin but however 
it is preferred most of the times as there is no prerequisite to control the INR value or to monitor 
it using aPTT since it is safer in comparison to the Unfractioned Heparin.  
 LMWH optimal usage dose according to the body weight is from one to two injections (subcutaneously) 
per day and it is primarily used in patient with Deep Venous Thrombosis (DVT) (Rydberg et al.1999). 
LMWH is proven to be safe and useful in patients who have undergone general surgeries other 
than cardiovascular kind (Hirch et al. 2001).  
Using unfractioned Heparin instead of LMWH, albeit very effective but less safe, requires the 
control of INR. 
 
Structure  
Heparin is a linear heterogeneous polyelectrolyte molecule which exhibits acidic pH and negative 
charge. As a chemical structure, Heparin is an acidic anionic glycosaminoglycan polysaccharide. 
Its large linear polymer is assembled with repeating sulfated disaccharide units of glucosamine 
and induronic acid. In glucosamine and induronic acid, some of the hydroxyl groups are 
substituted by sulfates. Dissociation of sulfate groups is a proof for Heparin’s acidic nature [5].  
The chemical structure of Heparin is presented below (figure 4): 
 
Figure 4: chemical structure of Heparin [6] 
As presented in the figure, Heparin is made of a long chain of glycosaminoglycan polysaccharide with repeated sulfated disaccharide 
units glucosamine and induronic acid.  
Heparin is produced and stored together with histamine only in the granules of the mast which are 
present excessively in the liver, lung, intestinal mucosa, skin, nasal mucosa and conjunctiva tissues [5]. 
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Mechanism of action 
The following paragraphs, with the references therein, are adapted from Hirch et al. 2000. 
Heparin was isolated from liver and discovered by Mclean in 1916 (Mclean 1916). But it was 
Brinkhous together with his associates (Brinkhous et al. 1939) who proved that Heparin needs 
another plasma cofactor to activate its anticoagulant action. This cofactor was later named as 
antithrombin III (AT-III) which is also known nowadays as antithrombin (AT).  
Rosenberg and Bauer (1994) explained the interactions between AT and Heparin where an 
arginine-reactive site of AT molecule undergoes a conformational change as a result of Heparin 
binding to this molecule at its lysine site. Arginine-reactive site of AT on the other hand is where 
this molecule inhibits the active serine center of Thrombin and other coagulation enzymes. This 
conformational change would therefore convert AT from a slow progressive inhibitor of 
Thrombin and coagulation enzymes into a fast active inhibitor of Thrombin and factor Xa. AT 
thereby binds covalently to the active serine centers of the clotting enzyme and together with 
heparin makes a ternary complex. Heparin can then become free and useful again by dissociating 
itself from the complex, after when clotting enzyme is inhibited by AT.   
The mechanism is presented below (figure 5): 
 
Figure 5: addition of the AT to the clotting enzyme together with Heparin (Hirch et al. 2001) 
The figure above figure presents inactivation of clotting enzymes by Heparin. In the very above illustration, it could be observed 
that antithrombin III (AT III) is a slow inhibitor of the clotting enzyme without being bound to heparin. The middle illustration 
presents the formation of ternary complex where the binding of Heparin to AT III makes conformation change to AT III and 
transforms it from a slow into a fast inhibitor of the clotting enzyme. The lowest illustration shows the dissociation of Heparin 
from the covalently bound AT III to the clotting enzyme (IIA, IXa, XIa or  XIIa). 
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It was discovered later that the site at which AT binds to Heparin is a unique glucosamine unit 
being contained within a pentasaccharide sequence. 
The fraction of Heparin which binds to AT and is responsible for most of its anticoagulation effect 
is only one third of this drug administered to patients. 
At therapeutic concentrations of Heparin, the remaining two thirds of the administered dose 
presents a minimal anticoagulant activity but however when the concentration is greater than that 
used during treatment, both of low and high affinity Heparin catalyze the AT inhibition of the 
heparin cofactor II (catalyzes the inactivation of factor IIa). 
A numbers of coagulation factors are inactivated by the Heparin -AT complex including 
thrombin (IIa) and factors Xa, XIIa, XIa and XIIa, where among them the most inhibited is 
thrombin and factor Xa.  
As it could be seen in the following figure, Heparin must bind to clotting enzyme and at the same 
time to AT in order to inhibit thrombin. For inactivation of factor Xa, Heparin needs to bond 
only to AT as binding to clotting enzyme is not so important in that case. 
When a Heparin molecule contains less than 18 saccharides, then it is unable bind to AT and 
thrombin at same time because of being too short and therefore this molecule of Heparin cannot 
catalyze thrombin inhibition. But on the other hand, very small heparin molecules also contain 
high-affinity pentasaccharide sequences, meaning that they are able to catalyze inhibition of 
factor Xa by AT. 
Heparin by inactivating thrombin, not only inhibits the formation of fibrin, but also the activation 
of factors V and factor VIII which are dependent on the Thrombin. 
Anticoagulant activity of heparin is variable, because as mentioned before only one third of 
molecules of Heparin functions as anticoagulant. The chain length of the molecule of Heparin 
does also affect its anticoagulant profile and its rate of elimination so that the higher molecular 
weight the sooner Heparin is removed from the circulation. This lower rate of removal of lower 
molecular species of Heparin results in the storage of these molecules in the body. 
Anti-coagulation drugs and mechanism 
Natalia Andersen and Hossein Khademi 
 
30 
 
The following (figure 6) presents the mechanism of AT-Heparin complex:  
 
Figure 6: mechanism of AT-Heparin complex (Hirch et al. 2001) 
The ternary AT-Heparin complex can make ternary complex and result in the inhibition of factors XIIa, Xia, IXa, Xa and IIa 
(activated thrombin) directly. But however the covalently bonded complex of AT to activated thrombin (IIa) also results in the 
indirect inhibition of the factors regulated by Thrombin mainly factor V and VIII. Thrombin and factor Xa are also the most 
sensitive factors to the AT-Heparin complex effect meaning that they are inhibited the most by this complex  
 
Heparin can also bind to the Von Willebrand factor and therefore inhibit platelet functions 
dependant on this factor such as the binding to the endothelial cells.  
Moreover, Heparin also binds to the platelets and induces or inhibits platelet aggregation 
depending on the experimental conditions in vitro. 
This anticoagulant can result in Heparin induced bleeding not due to its anticoagulant activity but 
because of its interactions with the platelets and the endothelial cells. 
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Pharmacology of Unfractioned Heparin (UFH) 
 Recommended methods of applying UFH are continuous intravenous infusion and subcutaneous 
injection. In the case of subcutaneous injection starting dose must be sufficiently large to 
compensate for lower bioavailability of Heparin in this way. To get an instantaneous 
anticoagulation result, the drug has to be injected intravenously. 
 In below (figure 7), the mechanism and interactions of Heparin in blood fluid is presented. When 
circulating in blood, heparin associates with many different plasma proteins, which causes lower 
bioavailability of this anticoagulant at low concentrations. This is therefore the reason for the 
diversity of anticoagulant effect of Heparin in patients with thromboembolic disorders and also a 
proof to Heparin resistance phenomenon in the laboratory. In order to further complicate its 
pharmacokinetics, Heparin also associates with endothelial cells and the macrophages.  
 
 
Figure 7: the mechanism and interactions of UH in the blood fluid (Hirch et al. 2001) 
When heparin (small black dot) gets into the blood circulation it links with several plasma proteins and has the ability to associate 
itself with the endothelial cells (EC), macrophages (M) and antithrombin III (ATIII). The only kind of Heparin able to bind with 
ATIII is the high affinity pentasaccharide type, but binding to the other cell and proteins is not dependant on its ATIII binding site. 
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Elimination of Heparin occurs by combining two mechanisms characterized as rapid saturation 
mechanism and also the slower first-order mechanism. The first mechanism carried out by 
binding of Heparin to receptors on the macrophages and the endothelial cells (figure 7) where 
Heparin is broken down into its subunits. The slower first-order mechanism consists of the 
excretion by the kidneys (renal).  
When present in therapeutic doses, Heparin is mainly removed quickly through the rapid 
saturation mechanism. The dose effect relationship of Heparin is nonlinear at the therapeutic 
range as presented below (figure 8). Moreover, the intensity and the clotting time of Heparin’s 
action increases disproportionately by increase in dose at the therapeutic range. Therefore, for 
example, the biological half-life of heparin after intravenous administration of 25 IU / kg being 
about 30 minutes increases to 60 minutes upon intravenous administration of 100 IU / kg and 150 
minutes after intravenous administration of 400 U / kg. 
 
Figure 8: the dose effect relationship of Heparin (modified from Hirch et al. 2000) 
Low doses of Heparin are eliminated from plasma through rapid saturation mechanism. Therapeutic doses of heparin are removed 
from the plasma by mainly by the rapid saturation mechanism but also by the slower, nonsaturable, first-order mechanism. Finally, 
very high doses of heparin are predominantly removed through the slower, nonsaturable, first-order mechanism 
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Low Molecular Weight Heparin and its differences to the UFH 
In 1976, Johnson et al. and Anderson et al.  contributed that the impact of small molecular 
fractions of the standard Heparin on aPTT decline as the size of the molecule was reduced while at 
the same time anti-Xa activity was still preserved. This could be explained by the fact that the 
effect of Heparin on aPTT (in UFH) mainly derives from its anti-IIa activity.   
Low Molecular Weight Heparin is made by enzymatic or chemical depolymerisation of Heparin. 
The result is a particle with size of one third of Unfractioned Heparin molecules.  
Differences in coagulation way of working, pharmacokinetics and other biological properties 
between the LMWH and the UH can be explained by the relatively weaker binding of LMWH to 
plasma proteins and the proteins released from cells. 
LMWHs have lower ability than UFH in the inactivation of thrombin, because their smaller 
particles cannot be combined with both AT and thrombin. These fragments have however, the 
same ability as larger particles to inactivate factor Xa, because the simultaneous connection of 
thrombin and AT is not a necessary for anti-Xa activity. LMWH are removed from the body 
mainly through the kidneys. Therefore, patients with renal insufficiency have extended duration of 
LMWH biological half-life. LMWH have a longer plasma half-life, better bioavailability in 
comparison to small doses of UFH and a more predictable dose-effect relationship. 
Anticoagulant action of LMWH, just like UFH, involves the activation of AT. AT III is interacting with 
specific pentasaccharide sequence, which is composed by less than one third of LMWH molecules.  
To create a complex with AT and thrombin, LMWH chain must consist of at least 18 units of 
sugar (including pentasaccharide). Only a small number of LMWH molecules are therefore able 
to inactivate thrombin through the appropriate length of chain.  
On the other hand, all LMWH molecules contain a high affinity pentasaccharide sequences 
capable of catalyzing the inactivation of factor Xa. The ratios of anti-Xa activity to antithrombin 
activity in the case of UFH are almost equal. This is because in practice all UFH molecules 
contain at least 18 units of sugar. In LMWH preparations available on market this ratio varies 
between 2 and 4, depending on the molecular weight distribution in the preparation. 
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Direct Thrombin Inhibitors (DTIs) 
Direct Thrombin Inhibitors (DTIs) are a group of new anticoagulation drugs used against the 
clotting process. There are two groups of these inhibitors: 
- Bivalent: Being formed from minimum two or more subunits bound together making a 
single unit molecule. Hirudin and Bivalirudin belong to this group of DTIs. 
- Univalent: Being formed of one unit. Argatroban belong to this group of DTIs. 
In below (figure 9), main difference in mechanism of these groups is presented and compared to Heparin.  
 
Figure 9: mechanisms of Heparin compared to the mechanisms of DTIs (Di Nisio et al. 2005) 
The two groups of DTIs act in two different ways. The first way is to inhibit the soluble thrombin and the second way is to inhibit 
the fibrin-bound thrombin. In both of these ways, univalent DTIs only inhibit the active site of thrombin, while bivalent DTIs 
occupy and thereby inhibit the active site and in Exosite 1 in thrombin.  Fibrin can only bind to thrombin through Exosite 2. When 
thrombin is bound to fibrin through the Exosite 2, Heparin-AT complex is unable to inhibit the active site, whereas it is able to 
inhibit the active site in soluble thrombin where Exosite 1 is free and could be used for the initial binding with the Heparin. 
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In below (table 1), basic information about three different DTIs is presented: 
 
Hirudin Bivalirudin Argatroban 
Molecular mass in Da 7000 1980 527 
Site(s) of interaction with 
thrombin 
Active site and 
Exosite 1 
Active site and 
Exosite 1 Active site 
Renal clearance Yes No No 
Plasma half-life in min. 60 25 45 
Table 1: comparison of the properties of Hirudin, Bivalirudin and Argatroban (modified from Weitz and Buller 2002) 
Molecular mass in Daltons, site(s) of interaction with thrombin, Renal clearance (method of clearance) and plasma half-life in 
minutes for Hirudin and Bivalirudin (bivalent DTIs) and Argatroban (a univalent DTI) 
 
Moreover, the mechanism of interaction of Thrombin with different DTIs is compared to 
Heparin in the following (figure 10): 
 
Figure 10: interactions of different groups of DTIs with thrombin compared with that of Heparin (Warkentin 2004) 
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As it could be seen, the above part of the figure from the left presents the thrombin enzyme along with its catalytic active site 
(apolar site), the fibrinogen binding site (Exosite 1) and its Heparin binding site (Exosite 2). The above middle illustration shows 
the mechanism by which the AT-Heparin complex would move towards the soluble thrombin and the location of the bindings. 
The above right illustration shows the fibrin-bound thrombin where Exosite 2 is now inhibited by fibrin and therefore the 
Heparin-AT complex is unable to make a ternary complex with thrombin. The lower left part of figure shows the mechanism by 
which r-Hirudin or Hirudin inhibit the catalytic active site and Exosite 1 where the C-terminus inhibits Exosite 1 and the core N-
terminus inhibits the active site. Similarly in the middle below illustration, Bivalirudin which is almost 3 times shorter inhibits 
Exosite 1 and the catalytic active site of thrombin. The below left side of the figure illustrates the mechanism of the univalent 
DTIs such as Melagatran or Argatroban which are only capable of inhibiting the catalytic active site of thrombin. 
The following paragraphs would present a more detailed description of the DTIs Hirudin, 
Bivalirudin and Argatroban. 
 
Hirudin and its derivatives 
The following 3 paragraphs, with the references therein, are adapted from Lefkovits and Topol 1994.  
Leeches were primarily used for medicinal purposes in the ancient Greece where they were called 
Hirudo medicinalis. But in 1884 the antithrombotic characteristics of leeches’ saliva was presented 
by Haycraft and Hirudin was later successfully discovered by Markwardt in 1950s. During that 
time the structure of Hirudin was characterized and cloned and families of Hirudin-like peptides 
including Hirugens or Hirullins were developed deriving from the original structure of Hirudin.  
The natural Hirudin extracted from the leech’s saliva is the original thrombin inhibitor which is 
capable of forming the most powerful, tight and highly stable noncovalent complex with 
thrombin. Hirudin is a protein composed of 65 amino acids with three disulfide bridges and its 
molecular weight is approximately 7000 Da. Different isoforms of Hirudin slightly differ in the 
number of amino acids, but nonetheless they still retain similar anticoagulant activity as Hirudin. 
Hirudin and its isoforms all have the three disulfide bridges and a residue of sulfated tyrosine in 
their sixty third positions. Recombinant Hirudin has been developed by recombinant DNA 
technology where it has an identical amino acid sequence as the original Hirudin but with or 
without the sulfated tyrosine in the sixty third position. Sulfate groups are significant in the 
binding of Hirudin since a molecule of Hirudin without them has a 10 fold reduction in its 
affinity to thrombin, albeit that the binding is still strong enough.  
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 The molecule of Hirudin is made of a polypeptide chain and therefore has two specific regions 
of -NH2 terminal in the core and –COOH terminal in the tail. The N-terminal of Hirudin is the 
site of Hirudin that occupies and inhibits the active catalytic site of thrombin while the 
carboxylic terminal inhibits the anion binding Exosite 1 site of thrombin. When an initial ionic 
interaction is established following the inhibition there would be a rearrangement of the 
thrombin-Hirudin complex to form a stronger bond. Furthermore, other studies have shown that 
but there are also multiple other contacts between Hirudin and thrombin apart from the three 
binding sites allowing Hirudin to be bound tightly over an extended region of thrombin. 
Therefore these qualities have allowed Hirudin to be specific for the inhibition of thrombin 
without any interaction for other coagulation enzymes. 
In contrast to the covalent bond of AT-thrombin complex in the case of Heparin, the binding of 
Hirudin to thrombin is noncovalent, albeit that is still is very strong and with high affinity. This 
is the reason for the irreversibility of the bond of thrombin-Hirudin (Warkentin 2004).   
 
Bivalirudin 
As mentioned before, Bivalirudin also belongs to the bivalent DTIs but the first difference 
between this DTI and Hirudin is that it has a shorter polypeptide chain build from only 20 amino 
acids (Weitz and Buller 2002).  
Due to being a shorter polypeptide in comparison to Hirudin the molecular mass of Bivalirudin is 
also smaller by being 2180 Da.  Bivalirudin is an analogue of native Hirudin (hirulog), since the 12 
amino acids residue of its carboxyl terminal are isolated from the Hirudin amino acid residues 53-
64. The Carboxylic terminal binds with the Exosite 1 just like Hirudin and the N-terminus being 
made of 4 amino acids residue bind the active catalytic site of thrombin. The remaining 4 amino 
acids residue, which is in fact a four glycine residue, connects the two segments together. The 
binding of Bivalirudin to thrombin shows primarily no reversibility but it does then slowly 
transform to reversible binding kinetic once the cleavage of Bivalirudin has occurred at the third 
and fourth position amino acids (Arg and Pro). Following this breakdown fibrin/fibrinogen would 
compete with the remaining of Bivalirudin for thrombin (Warkentin 2004).  .  
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The structure of the polypeptide of Bivalirudin along with its mechanism is presented in the 
following (figure 11): 
 
Figure 11: the polypeptide sequence of Bivalirudin and its mechanism of inhibition of thrombin before and after its 
proteolytic cleavage (modified from Warkentin 2004) 
As it could be seen above the polypeptide of Bivalirudin consists of 20 amino acids where the 12 amino acid residue in the C-
terminus have derived from Hirudin (Lepirudin). This residue binds to Exosite 1 quite similar to Hirudin and its derivatives. The 
4 amino acids residue of the N-terminus would bind to the Active catalytic site of thrombin while the remaining four glycine 
amino acids residue would connect the two chains together. In below to the right the mechanism of binding of this DTI is 
presented after its proteolytic cleavage. The cleavage would interrupt the entire inhibition mechanism since the remaining chain 
of Bivalirudin would have a lower affinity for thrombin and therefore fibrin/fibrinogen would compete with this DTI for 
inhibition. This would therefore enable a reversible action for the inhibition and for thrombin to act again in the cascade 
 
The main mechanism of Bivalirudin, like the other DTIs, is to inhibits all thrombin catalysed or – 
induced reaction, including also fibrin formation. Furthermore it does also inhibit the activation 
of factors V, VII, XIII, protein C and the platelet aggregation [7]. 
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Argatroban  
Argatroban is a synthetic molecule that derives from L-arginine. The chemical structure of this 
DTI which is presented below (figure 12) contains four asymmetric carbons where one of the 
chiral carbons has an R configuration and an S configuration. A solution of Argatroban contains 
R and S stereoisomers at a ratio of 65:35. The chemical formula of Argatroban is 
C23H36N6O5S•H2O and this univalent DTI has the molecular weight of 526.66 Da [8].  
 
Figure 12: the chemical structure of Argatroban with the chiral carbons in circles [modified from 8] 
The figure presents the chemical structure of Argatroban’s molecule where the asymmetric carbons have been circled. The 
molecule is monohydrate which means that there is a water molecule bound to its structure, a fact which is not so clear in the 
figure is that this water molecule makes hydrogen bonds to the molecule.  
Argatroban could be described as a white and odourless solid powder. It is easily soluble in 
glacial acetic acid, slightly soluble in ethanol, and completely insoluble in acetone, ethyl acetate, 
and ether. Argatroban’s pharmaceutical product is described as a sterile clear and slightly viscous 
injection solution which is colourless to pale yellow. This DTI is available from is available in 2.5 
ml vial solution where there would be 250 mg of Argatroban. Therefore each ml of the sterile 
solution contains 100 mg Argatroban where other inert ingredients are 750 mg D-sorbitol and 1000 
mg dehydrated alcohol [8].  
This univalent DTI was discovered in the 1970s by Shosuke Okamoto and clinically used for the 
first time in Japan in the early 1980s. It was later adapted for the arterial thrombosis and acute 
cerebral thrombosis. The other applications of this DTI are to treat patients with deficient 
Antithrombin undergoing haemodialysis as well as treating patients with Heparin Induced 
Thrombocytopenia (HIT) (Walenga 2002) which could be because it does not interact with the 
Heparin Induced antibodies [8]. 
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Mechanism of action  
As presented before (figure 10), due to being a univalent DTI, Argatroban can only binds to the 
active catalytic site of thrombin. Argatroban’s mechanism of action is to interact with thrombin in a 
reversible manner similar to Bivalirudin. Argatroban has a highly selective interaction of thrombin 
where its thrombin inhibition constant (Ki) is 3.8 µM (Walenga 2002). While it is capable of 
inhibiting thrombin induced reactions (control of factors V, VIII and XIII, activation of protein C 
and the platelet activation) it has no effect on the other serine protease coagulation enzymes [8].  
The following paragraph, with the references therein, is adapted from Walenga 2002. 
A significant advantage of Argatroban compared to Heparin is that it can penetrate and inhibit the 
thrombin bound to fibrin effectively. This would give this DTI an upper hand in the treatment of 
older fibrin associated thrombi which are more organized. This advantage is not only limited to the 
comparison of Argatroban with Heparin, but also in comparison to other DTIs such as Hirudin. 
Where only a 2-fold increase in concentration of Argatroban is needed for it to inhibit the fibrin 
bound thrombin (in vivo and in vitro), a 23-fold increase in concentration of Hirudin is needed to 
inhibit the fibrin bound thrombin in vitro and a 4000-fold increase is need for it to inhibit fibrin 
bound thrombin in vivo. Moreover, a 500-fold increase of concentration in vitro and a 5000-fold 
increase of concentration in vivo is need for Heparin to inhibit the fibrin bound thrombin.  
The difficulty of the binding of Heparin to the fibrin bound thrombin which was presented before 
(figures 9 and 10) is because the Heparin chain of the Heparin-AT complex needs to place itself 
on Exosite 2 which is the fibrin bind site at the time of the formation of the ternary complex and 
therefore a huge increase in the concentration of Heparin is needed to inhibit the fibrin bound 
thrombin for this anticoagulant. 
 
Pharmacokinetics  
The following paragraph, with the references therein, is adapted from Walenga 2002. 
When measured and monitored by activated Partial Thromboplastin Time (aPTT) method, 
Argatroban reaches its steady plasma level anticoagulant effect after 1-3 hours of intravenous 
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infusion. This duration is reduced when Argatroban is administered orally in the form of pill. 
There is a low intra-subject and inter-subject variability in the plasma level concentration effect 
response of Argatroban. The concentration of Argatroban in plasma increases proportionally 
with its infusion dose until up to 40 µg of Argatroban per kg of body weight per minutes after IV 
infusion, where they are both well correlated to the steady-state anticoagulant effect of 
Argatroban. The dose response curve of Argatroban is predictable and gentle which provides a 
wide margin of safety during the dose titration. When the dose infusion is stopped the aPTT 
would return to its normal value within 2-4 hours. The elimination half-life of Argatroban is 39-
51 minutes and it is not affected by gender, age and renal function. 
The following (figure 13) presents the aPTT and ACT relation of Argatroban to the infusion dose 
which as mentioned before is also proportional to the concentration of Argatroban in plasma:  
 
Figure 13: the aPTT and ACT relation to the infusion dose and plasma concentration of Argatroban in vivo [8] 
The figure presents the aPTT in seconds and ACT in seconds relation to the infusion dose of Argatroban (mcg = 10 µg) of 
Argatroban per kg of body weight per minutes after IV infusion) and the concentration of Argatroban in plasma (mcg = 10 µg) of 
Argatroban in ml of plasma) in vivo. As it be noticed the dose response curve of Argatroban is quite shallow and predictable 
which allows this drug to be safely administered to patient. 
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Metabolism 
The following paragraph, with the references therein, is adapted from Walenga 2002. 
Argatroban is metabolized very fast in the liver and would be excreted in the faeces through the 
bile. Argatroban would be converted into three different metabolites which are also presented 
below (figure 14). Among these metabolites, which are M1, M2, M3 and M4, M1 still retains a 
very weak antithrombin effect despite the fact that this could not be verified through routine 
clinical intravenous dosing of Argatroban. The other important fact to mention about the 
metabolism of Argatroban is that this DTI does not prompt the formation of antibodies which 
would diminish its anticoagulant effect, prolong its half-life or even enhance its activity. 
 
Figure 14: different metabolisms of Argatroban (modified from Walenga 2002) 
As it could be seen by looking at the top of the figure, the chemical structure of Argatroban is presented. This chemical structure 
would be metabolized in the liver into four different metabolites M1, M2, M3 and M4 which are all presented in the figure. M1 is 
the isolation of the double aromatic structure of Argatroban with a reduction of the primary amine in the ring which prompts its 
atom to make a double bond. This metabolite would still retain its very modest antithrombin effect. M4 one the other hand is the 
result of the isolation of the same structure, but the oxidation of the primary amine in the ring which adds a phenol group to the 
aromatic nitrogen. M2 and M3 are the result of a cleavage at the sulfur connection with the double ring resulting in M2 being the 
double aromatic group and the remanent of Argatroban structure in M3.  
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aPTT method 
 
Overview 
Of the several methods adapted to test the efficiency of the coagulation mechanism of the body 
or an anticoagulant activated Partial Thromboplastin Time commonly abbreviated as aPTT is a 
relatively easy and common method. The method is used to measure the efficiency of the 
intrinsic and common pathway of the coagulation cascade. In order to understand the method in a 
better way, the following paragraphs which are largely adapted from UK Lab Tests Online [9]. 
 
Applications 
The aPTT test would measure the amount of time that it takes in seconds for a clot to appear in 
plasma of a test tube when reagents are added to it. 
This test is traditionally applied along with the Prothrombin Test (PT), which measures the 
efficiency of the extrinsic and common pathway, in order to investigate the reason of coagulation 
disorders such as bleeding or thrombosis in patients. The aPTT is used as a common pre-surgical 
test in patients with bleeding tendencies in surgeries that carry an increased risk of blood loss.  
The other function of this test is to monitor the activity and efficiency of anticoagulants such as 
Heparin on patients.  
 
Process and the determination of factor deficiency 
In this test a sample of blood plasma is taken into a vacutainer with citrate added in order to bind 
with the calcium and prevent coagulation of the sample. In order to activate the intrinsic pathway 
an activator reagent such as particles and phospholipids are added and then calcium is added 
back to start coagulation and the time which it takes for the plasma to blot is measured. When 
anti-coagulants are added to the plasma sample, there is a reasonable expectation that the test 
would be prolonged compared to the test with the absence of the anticoagulants. However if the 
aPTT test is abnormally prolonged but not due to the anti-coagulant effect, then there is a 
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hypothesis that the intrinsic and the common pathway of the coagulation cascade are inefficient 
due to the lack of a necessary factor in the cascade. In order to test the validity of this hypothesis 
the blood plasma would be mixed with the plasma of another donor which has all the necessary 
clotting factors. If the aPTT of the new sample is ‘correct’ or in other word relative to the normal 
measure then there is a conclusion that the missing factor of the coagulation cascade in the 
patients plasma was provided by the new plasma and therefore the patient does in fact lack a 
necessary factor in the intrinsic or common pathway of the coagulation cascade. Specific tests 
are therefore followed to determine precisely which factor is missing in the patient. However, 
even in the reflection of normal aPTT, there is a moderate possibility that single factors are in 
lack in the plasma. This is because the lack of these single factors would not alter the aPTT 
noticeably until when they have decreased to 30% or 40% of their normal amount. 
 
Specific and non-specific inhibitors and their effect on the aPTT test 
As mentioned before, when aPTT is prolonged, the usual assumption is that the deficiency of a clotting 
factor. The other possible conclusion from the prolonged aPTT is the presence of the specific or 
unspecific inhibitors in the plasma which is affecting the coagulation ability of the blood. These 
inhibitors may be the antibodies which target certain coagulation factors specifically such as Factor 
VIII antibodies or they may be non-specific inhibitors which bind with the phospholipids on the surface 
of the platelets thus preventing their activation. Lupus inhibitors or anticoagulants are of this group.  
 
Lupus Anti-coagulants (LA) and their effect on the aPTT test 
Lupus inhibitors or anti-coagulants are proteins that work as nonspecific inhibitor of the of the 
coagulation cascade factors by binding with the phospholipids on the surface of the platelets and 
preventing their activation and further role in the coagulation cascade. The presence of Lupus 
inhibitors in the plasma increases the risk of clots in the veins and arteries and by blocking the 
blood flow increase the risk of strokes, heart attacks, deep vein thrombosis, pulmonary embolisms 
and frequent miscarriages in the second and third trimesters of pregnancy. The presence of Lupus 
inhibitors or anti-coagulants may not be detected by aPTT since the reagents added during this test 
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have phospholipid structures that could bind to the Lupus inhibitors and thereby prolong the aPTT. 
Therefore the presence of Lupus inhibitors could be detected by a LA-sensitive aPTT.  Dilute 
Russell Viper Venom Test is another similar test which could also be applied  
 
Use of aPTT in the heparin therapy 
Another common application of the aPTT test which was mentioned before is to administer and 
monitor the activity of anti-coagulant drugs in patients with coagulation disorders or post-surgery 
patients who have an increased risk of thrombosis. Heparin is an anti-coagulant which is 
administered through IV or injection in order to prevent and treat thromboembolisms. Too much 
of this drug can cause excessive bleeding in patients while too low doses of this drug can cause 
the patient to clot. Therefore this drug should therefore be monitored when given in the 
therapeutic doses and aPTT is hence used to monitor heparin therapy. When heparin is tested 
using aPTT the result is usually expected to be 1.5 to 2.5 times greater than that of the normal 
sample without heparin. The heparin therapy of an abnormal aPTT is rather difficult. Therefore 
in patients with irregular bleeding or clotting a hypercoagulability test is applied with aPTT. 
Reptilase test which is alike to aPTT is also used in abnormal aPTT.  
 
Pre-analytical adjustments to aPTT 
In order to prevent a prolonged aPTT measure several factors have to be considered: 
1. The plasma sample should be sufficient. The anti-coagulant to the blood ratio should be 9:1. 
2. The plasma sample has to be protected from heparin contamination since this common 
problem can arise when the blood sample collected from the intravenous lines is kept 
open to heparin flushes. 
3. The clotting in the sample should be avoided before the aPTT test start (before the 
reagents are added). 
4.  Patients with irregular levels of haematocrit could get an altered aPTT and this has to be 
noted beforehand. 
5. The aPTT is relatively insensitive towards Warfarin even though it could be affected by it. 
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Experiments 
 
Overview 
To begin with, the method using in the experiments is activated Partial Thromboplastin Time 
(aPTT). The experiments are carried out at clinical biochemistry department of the Roskilde 
Hospital. The assay which was given to us has been developed by a Jane Brandholdt in 1988. 
However there are slight modifications to the original assay in our experiments.  
In this assay, the volume of plasma, the volume of platelin, the volume of saline, the total 
volume of the solution, the concentration of Ca2+, and the concentration of the anticoagulant are 
the important variables. The details of the assay would be explained later on. 
The first experiment is to determine the reference clotting time of the plasma. In this experiment 
the prepared sample of plasma, platelin and Ca2+ all in equal amounts of 100 µl and 10 µl of 
saline would be added to a glass tube and the time it takes for the first clot to appear in the glass 
tube would be noted. The reference clotting is calculated after several repetitions as an average 
of the results. This value is used as a reference comparison for other experiments. 
In the second experiment the effect of the change in the concentration of Ca2+ on the clotting 
time of blood is investigated. 
In the third experiment the effect of the dilution of plasma and the coagulation factors on the 
plasma on the clotting time of blood is investigated. 
In the fourth experiment the dose-effect of Heparin on the clotting time is investigated. 
In the fifth and the final experiment the dose-effect of Argatroban on the clotting time of the 
plasma sample is investigated. 
The protocols of these experiments including the equipments, procedures and calculations, and 
variables are included in the appendices. 
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First experiment: determination of the reference clotting time 
 
Method 
In this experiment, the default method of the assay was used in order to obtain the reference 
clotting time which is to be used later for comparison in the other experiments. 
 A solution of 0.025 M Ca2+ was placed inside a 37 °C water bath for 8 minutes and then 100 µl 
of platelin and 100 µl of plasma were added to a small glass tube which was already inside the 
water bath for at least 3 minutes. 10 µl of saline was also added and the solution was shaken and 
left in the bath for about 6 minutes. Thereafter 100 µl of the warmed Ca2+ was also added to the 
solution in the glass tube and the approximate time for the first clot to appear from the addition 
of Ca2+ was measured using a stopwatch and noted down. The method was repeated for a couple 
of times in order to obtain an accurate average of the clotting time. 
 
Results 
Trial no. Reference clotting time 
1 43.06 s 
2 43.32 s 
3 46.59 s 
4 40.53 s 
5 45.75 s 
6 43.18 s 
7 43.53 s 
8 40.84 s 
9 39.82 s 
10 40.41 s 
11 38.09 s 
12 39.67 s 
Average 


 	
 
Table 2: the table presents the values of the 
measurements of the reference clotting time 
along with its calculated average.  
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Second experiment: the effect of the change of [Ca2+] on the clotting time 
 
Method 
 In this experiment, the effect of the change of Ca2+ concentration on the clotting time of the 
plasma sample was investigated. 
In the beginning, different solutions of Ca2+ with different concentrations were prepared. The 
bottle of 0.025 M Ca2+ was used to make nine solutions of Ca2+ with the dilutions of 0.9 to 0.1 in 
saline. Thereafter a bottle of 0.25 M Ca2+ was used to make eight solutions of Ca2+ with the 
dilutions of 0.9 to 0.2 in saline. All of these solutions of Ca2+ were warmed in the 37 °C water 
bath for 8 minutes and then added instead of the Ca2+ solution used in the first experiment’s 
method. The time taken for the clot to appear since the addition of each Ca2+ was measured and 
noted down. The method was repeated twice for each different solution of Ca2+ and the average 
of the two clotting times were calculated for each concentration of Ca2+. 
The experiment was divided into two different steps: 
1) Solution preparation 
2) Measurement of the clotting time 
 
Results  
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Volume of Ca2+ solution used = 100 µl 
Total volume of solution = 310 µl  
Calculations are presented in the protocols for the second experiment in the appendices. 
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Measurement of the clotting time 
Glass 
no. 
Concentration 
of Ca2+ bottle 
Ca2+ 
dilution 
[Ca2+] in the 
glass tube 
Clotting time 
set A 
Clotting time 
set B 
Average 
clotting time 
1 0.025 M 1.0 0.00806 M 42.07 s 42.07 s 42.07 s 
2 0.025 M 0.9 0.00726 M 39.94 s 42.66 s 41.30 s 
3 0.025 M 0.8 0.00645 M 43.94 s 42.94 s 43.44 s 
4 0.025 M 0.7 0.00565 M 45.50 s 44.94 s 45.22 s 
5 0.025 M 0.6 0.00484 M 47.75 s 46.06 s 46.91 s 
6 0.025 M 0.5 0.00403 M 43.68 s 43.94 s 43.81 s 
7 0.025 M 0.4 0.00323 M 49.28 s 52.09 s 50.69 s 
8 0.025 M 0.3 0.00242 M 66.72 s 70.94 s 68.83 s 
9 0.025 M 0.2 0.00161 M 221.56 s 186.47 s 204.02 s 
10 0.025 M 0.1 0.00081 M 300.00 s  < 300.00 s  < 300.00 s  < 
11 0.250 M 0.9 0.07258 M 300.00 s  < 300.00 s  < 300.00 s  < 
12 0.250 M 0.8 0.06452 M 300.00 s  < 300.00 s  < 300.00 s  < 
13 0.250 M 0.7 0.05645 M 205.33 s 200.53 s 202.93 s 
14 0.250 M 0.6 0.04839 M 160.16 s 163.41 s 161.79 s 
15 0.250 M 0.5 0.04032 M 120.32 s 136.09 s 128.21 s 
16 0.250 M 0.4 0.03226 M 92.53 s 104.53 s 98.53 s 
17 0.250 M 0.3 0.02419 M 72.00 s 75.68 s 73.84 s 
18 0.250 M 0.2 0.01613 M 61.63 s 63.85 s 62.74 s 
Table 3: the table presents the values of the clotting time corresponding to different concentrations of Ca2+ 
Note: the values of the concentration of Ca2+ in glass tube, present in the fourth column of the table, are calculated according to 
the formula provided above and glass no. 1 presents the reference clotting time calculated in the first experiment 
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Graphs 
Measurement of the clotting time 
 
Figure 15: the graph presents the relation of the clotting time in seconds to the concentration of Ca2+ in Molar 
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Third experiment: the effect of the dilution of plasma on the clotting time 
 
Method 
In this experiment, the effect of the dilution of plasma on the clotting time of plasma was investigated.  
In the beginning the solutions of the diluted plasma in saline were prepared quite similar to the 
last experiment’s method. In this method 9 different solutions of plasma with dilutions ranging 
from 0.9 to 0.1 in saline were prepared in 9 plastic tubes. Each of these solutions was then added 
instead of the plasma added in the general method to find the reference clotting time in the first 
experiment. Each different dilutions of plasma were tested for two times and the average clotting 
time of plasma was calculated and written down.  
The experiment was divided into two different steps: 
1) Solution preparation 
2) Measurement of the clotting time 
 
Results 
Measurement of the clotting time 
Glass no. Plasma dilution Clotting time set A Clotting time set B Average clotting time 
1 1.0 42.07 s 42.07 s 42.07 s 
2 0.9 48.22 s 52.37 s 50.30 s 
3 0.8 58.16 s 60.41 s 59.29 s 
4 0.7 64.28 s 63.68 s 63.98 s 
5 0.6 73.37 s 70.66 s 72.02 s 
6 0.5 85.60 s 84.03 s 84.82 s 
7 0.4 89.03 s 92.72 s 90.88 s 
8 0.3 150.44 s 124.91 s 137.68 s 
9 0.2 183.32 s 198.78 s 191.05 s 
10 0.1 300.00 s  < 300.00 s  < 300.00 s  < 
Table 4: the table presents the clotting time corresponding to the different dilutions of plasma 
Note: The values of glass no. 1 is the reference clotting time calculated in the first experiment 
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Graphs 
Measurement of the clotting time 
 
Figure 16: the graph presents the relation of the clotting time in seconds to the plasma dilution 
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Fourth experiment: Heparin’s dose-effect on the clotting time 
 
Method 
In this experiment, there was an attempt to investigate the relation between the clotting time of 
plasma and the change of Heparin’s dose. 
In the beginning, different solutions of the diluted Heparin in saline were prepared. In this 
method 10 different solutions of Heparin with dilutions ranging from 0.0313 to 1 in saline were 
prepared in 10 plastic tubes. The dose of the Heparin drug used to make these dilutions was 100 
IU/ml. 10 µl of each one of these solutions was added instead of the saline in the original method 
to calculate the reference clotting time in the first experiment. The clotting time corresponding to 
each different Heparin solution was measured two times and the average clotting time was 
calculated and written down. 
The experiment was divided into two different steps: 
1) Solution preparation 
2) Measurement of the clotting time 
 
Results 
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Volume of Heparin solution used = 10 µl 
Total volume of solution = 310 µl 
Dose of Heparin = 100 IU/ml 
Calculations are presented in the protocols for the fourth experiment in the appendices. 
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Measurement of the clotting time 
Glass no. 
Heparin 
dilution 
Heparin dose 
in glass tube 
Clotting time 
set A 
Clotting time 
set B 
Average 
clotting time 
1 1.0000 3.2258 IU/ml 1800.00 s  < 1800.00 s  < 1800.00 s  < 
2 0.5000 1.6129 IU/ml 1800.00 s  < 1800.00 s  < 1800.00 s  < 
3 0.2500 0.8065 IU/ml 1800.00 s  < 1800.00 s  < 1800.00 s  < 
4 0.2170 0.7000 IU/ml 1007.01 s 1216.78 s 1111.90 s 
5 0.1860 0.6000 IU/ml 824.00 s 862.20 s 843.10 s 
6 0.1550 0.5000 IU/ml 789.06 s 834.00 s 811.53 s 
7 0.1250 0.4032 IU/ml 456.53 s 532.35 s 494.44 s 
8 0.0950 0.3060 IU/ml 295.00 s 299.72 s 297.36 s 
9 0.0625 0.2016 IU/ml 178.85 s 181.16 s 180.01 s 
10 0.0313 0.1008 IU/ml 134.56 s 130.91 s 132.74 s 
Table 5: the table presents the relation between the clotting times of plasma to different doses of Heparin 
Note: the measurements of glass no. 6 were repeated for 9 times in the beginning with variations of 1 to 5 minutes. However after 
the glass tube containing the Heparin solution was shook before taking Heparin, the two results had a variation of 5 seconds; 
therefore the same was applied to all. Moreover the values of Heparin dose in glass tube presented in the third column are 
calculated according to the formula provided above. 
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Graphs 
Measurement of the clotting time 
 
Figure 17: the graph presents the clotting time is seconds vs. the dose of Heparin in International Units per milliliters 
Note: the y-intercept is the reference clotting time being 42.07 s 
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Fifth experiment: Argatroban’s dose-effect on the clotting time 
 
Method 
 In this experiment, there was an attempt to investigate the relation between the clotting time of 
plasma and the change of Argatroban’s dose. 
In the beginning, different solutions of the diluted Argatroban in saline were prepared using a 
bottle 0f 100 mg/ml of Argatroban drug. In this method 6 different solutions of Argatroban with 
dilutions ranging from 0.01 to 0.465 in saline were prepared in 6 plastic tubes. Then using 4 of 
the prepared solutions before, 7 new different solutions of Argatroban were prepared. And 
finally using 6 of the latest solutions, 7 new different solutions of Argatroban were prepared. 
Overall, 20 plastic tubes with solutions of Argatroban ranging from 0.00125 to 46.5 mg/ml of 
Argatroban were made. 
Finally, quite similar to the method of the fourth experiment, 10 µl of each one of these solutions 
was added instead of the saline in the original method to calculate the reference clotting time in 
the first experiment. The clotting time corresponding to each different Argatroban solution was 
measured two times and the average clotting time was calculated and written down. 
The experiment was divided into two different steps: 
1) Solution preparation 
2) Measurement of the clotting time 
 
Results 
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Volume of Argatroban solution used = 10 µl 
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Total volume of solution = 310 µl 
Calculations are presented in the protocols for the fourth experiment in the appendices. 
 
Measurement of the clotting time 
Glass 
no. 
Argatroban 
Solution used 
Dilution 
Argatroban dose 
in plastic tube 
Argatroban dose 
in glass tube 
Clotting 
time set A 
Clotting 
time set B 
Average 
clotting time 
1 100.000 mg/ml 0.465 46.5000 mg/ml 1.50000 mg/ml 1800.00 s  < 1800.00 s  < 1800.00 s  < 
2 46.5000 mg/ml 0.735 34.1775 mg/ml 1.10250 mg/ml 1800.00 s  < 1800.00 s  < 1800.00 s  < 
3 100.000 mg/ml 0.220 22.0000 mg/ml 0.70968 mg/ml 1076.01 s 1115.00 s 1095.51 s 
4 100.000 mg/ml 0.155 15.5000 mg/ml 0.50000 mg/ml 981.68 s 1057.44 s 1019.56 s 
5 100.000 mg/ml 0.060 6.00000 mg/ml 0.19355 mg/ml 919.07 s 840.66 s 879.87 s 
6 6.00000 mg/ml 0.515 3.09000 mg/ml 0.09968 mg/ml 787.01 s 678.37 s 732.69 s 
7 100.000 mg/ml 0.020 2.00000 mg/ml 0.06452 mg/ml 721.41 s 672.13 s 696.77 s 
8 100.000 mg/ml 0.010 1.00000 mg/ml 0.03226 mg/ml 457.06 s 418.40 s 437.73 s 
9 6.00000 mg/ml 0.135 0.81000 mg/ml 0.02613 mg/ml 411.50 s 409.35 s 410.43 s 
10 1.00000 mg/ml 0.500 0.50000 mg/ml 0.01613 mg/ml 390.03 s 339.00 s 364.52 s 
11 1.00000 mg/ml 0.200 0.20000 mg/ml 0.00645 mg/ml 232.09 s 218.97 s 225.53 s 
12 1.00000 mg/ml 0.100 0.10000 mg/ml 0.00323 mg/ml 189.94 s 186.00 s 187.97 s 
13 2.00000 mg/ml 0.040 0.08000 mg/ml 0.00258 mg/ml 179.28 s 181.85 s 180.57 s 
14 0.10000 mg/ml 0.500 0.05000 mg/ml 0.00161 mg/ml 145.44 s 152.87 s 149.16 s 
15 0.08000 mg/ml 0.500 0.04000 mg/ml 0.00129 mg/ml 138.82 s 140.66 s 139.74 s 
16 0.04000 mg/ml 0.500 0.02000 mg/ml 0.00065 mg/ml 134.50 s 109.32 s 121.91 s 
17 0.10000 mg/ml 0.100 0.01000 mg/ml 0.00032 mg/ml 92.06 s 84.13 s 88.10 s 
18 0.01000 mg/ml 0.500 0.00500 mg/ml 0.00016 mg/ml 72.59 s 73.91 s 73.25 s 
19 0.00500 mg/ml 0.500 0.00250 mg/ml 0.00008 mg/ml 68.41 s 60.03 s 64.22 s 
20 0.00250 mg/ml 0.500 0.00125 mg/ml 0.00004 mg/ml 53.13 s 52.59 s 52.86 s 
Table 6: the table presents the relation between the clotting times of plasma to different doses of Argatroban 
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Graphs 
Measurement of the clotting time 
 
Figure 18: the graph presents the clotting time is seconds vs. the dose of Argatroban in milligrams per milliliters 
Note: the y-intercept is the reference clotting time being 42.07 s 
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Discussion 
 
The effect of changing [Ca2+] on the clotting time 
As it could be seen by looking at the results of the second experiment (figure 15), increasing the 
concentration of Ca2+ decreases the clotting time of the plasma until when there is a stable range 
where the clotting time becomes almost constant. When the concentration of Ca2+ is increased 
further than this range the clotting time would be prolonged again. 
In this context, several of the Vitamin-K dependent factors contain a gla residue in their amino 
terminal domain which could easily bind to several Ca2+ ions. These factors include VII, IX and X 
as well as protein C. Ca2+ facilitates the activation of the zymogens of these factors and therefore 
most of the coagulation cascade’s reactions need Ca2+ for catalysis. In most of the cases both the 
enzyme and the substrate bind to this ion and it is difficult to determine whether it is substrate or 
the enzyme or both that Ca2+ alters (Le Bonniec et al. 1992). 
This could explain why the presence of an optimal amount of Ca2+ is essential for the activation 
of these factors to proceed. The reaction kinetics of Ca2+ binding to and activating the coagulation 
factors would likely follow the rules of substrate binding in enzyme kinetics until all Ca2+ binding 
sites are occupied. At higher Ca2+ concentration, Ca2+ can likely bind unspecifically to negative 
sites on the factors and thereby inhibit their function due to changing their overall charge. 
Therefore when there is an excess amount of Ca2+ in the plasma (in vitro), and all the catalytic site of 
the enzyme and the substrate are occupied by the other Ca2+ ions, this ion would begin to inhibit 
other active sites of the enzyme or substrate and act as an inhibitor. This would therefore halt the 
activation of new zymogens and result in a longer clotting time. Therefore the clotting time of the 
plasma in vitro would be prolonged when too much of Ca2+ ion is added to the plasma. 
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The effect of diluting the plasma on the clotting time 
As it could be seen (figure 16), the dilution of the plasma leads to a prolonged clotting time. This is 
not so strange because the dilution of the plasma does in fact result in the dilution of the clotting 
factors. However the best fit line model for the relation of the clotting time to the dilution of the 
plasma is a reciprocal function which shows that the clotting time of plasma is equal to a constant 
times the inverse of the dilution factor of the plasma where this constant is approximately equal to 40.  
 
Dose effect of Heparin 
As it could be seen (figure 17), increasing the concentration of Heparin increases the clotting 
time of plasma. While, the relationship between the clotting time and dosage of Heparin is of a 
more linear nature linear in lower doses, it is more exponential when points with higher 
concentrations are included. But however there are two important discussion points about the 
curve that first of all it is not a steep curve as expected and second of all there is no asymptote 
when the dose of Heparin is very high. This would be further discussed at the end of this section 
where the dose-effect curves of Heparin and Argatroban are compared. 
Another important point in the discussion of the results is that, when the experiments with 0.1 
IU/ml of Heparin were made for several times and there was a big variation between the results, 
it was assumed that there was something wrong with the Heparin solution. Hence, the glass tube 
of Heparin was shaken before we taken and this provided very closer results. Therefore Heparin 
is likely to have a fair insolubility in saline. Moreover, as it could be seen, the variation of the 
results of the same dose shows that Heparin has a heterogeneous (alternating) anticoagulant 
activity and pharmacokinetic property, a fact which is also acknowledged by Hirch et al. 2001.  
 
Comparison with the clotting time of Heparin in vivo 
The result of the clotting time for therapeutic range dosage of Heparin in human body was about 
80 seconds according to the Heparin therapy experimental results of the clinical biochemistry 
department of Roskilde Hospital’s database. The results are a measure of Heparin’s effect in 
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vivo. The clotting time of plasma at the therapeutic range was more than 30 minutes in our 
experiments in vitro. The reason for this phenomenon which was also explained before 
(Pharmacology of UFH, Theory) is that Heparin is associated with many plasma proteins, 
macrophages and endothelial cells inside the body (in vivo). This would therefore lead to a lower 
bioavailability of Heparin in vivo than in vitro and a higher concentration of Heparin is needed in 
vivo than in vitro to reach the same clotting time. In order to understand this better an illustration 
of the dose-effect curve of Heparin in vivo is compared to in vitro in the following (figure 19): 
 
Figure 19: comparison of the dose-effect curve of Heparin in vivo and in vitro  
When the effect same dose of Heparin as in vitro is applied in vivo, a prolonged clotting time is expected and when the goal is to 
reach the same clotting time in both conditions, a higher dose needs to be applied in vivo that in vitro in order to compensate for 
the lower bioavailability of Heparin caused by its interactions with the plasma proteins, macrophages and the endothelial cells.  
 
Dose effect of Argatroban 
As it could be seen (figure 18), increasing the concentration of Argatroban increases the clotting 
time of the plasma. In lower doses of Argatroban, the clotting time rises steeply while it becomes 
more controlled and predictable as the dose of Argatroban increases and the clotting time almost 
reaches a maximum. Therefore, the dose-effect curve follows a saturation model where unlike 
the dose-effect curve of Heparin the asymptote of the clotting time is reached. This would 
indicate that the dose-effect curve of Argatroban in vitro is steeper and less shallow than Heparin 
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in the first glance even though that the unit of the dose measurement is different. This would be 
further discussed in the comparison of the dose-effect curves of Argatroban to Heparin later on. 
 
Comparison with the clotting time of Argatroban in vivo 
Albeit that we could not find an acknowledged proof for the interaction of Argatroban with other 
proteins and molecules in vivo like Heparin, the dose-effect curve of Argatroban in vivo which was 
presented before (figure 13) can be compared with the dose-effect curve of the results of 
experiments (in vitro) in order to compare the two. The comparison of these two which is presented 
below (figure 20) indicates that similar to Heparin, Argatroban has a more shallow and predictable 
dose-effect curve in vivo than in vitro. Therefore a fair conclusion of this is that Argatroban has also 
interactions with materials (such as plasma proteins, macrophages or the endothelial cells) other than 
thrombin. This would thereby provide a less bioavailability of this DTI in vivo than in vitro. 
 
Figure 20: comparison of the dose-effect curve of Argatroban in vitro and in vivo [modified from 8]  
The dose-effect curve of Argatroban in vitro has been taken from figure 18 (average result) while the in vivo dose-effect curve is 
taken from figure 13 where it has been modified. 
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As it could be seen the same dose of Argatroban applied in vivo and in vitro gives different clotting time where it would take 
longer in vitro than it vitro for blood to clot. On the other hand when the goal is to reach the same clotting time, a higher dose of 
Argatroban is needed to be applied in vivo than in vitro. 
 
Comparing the dose-effect curves of Argatroban and Heparin 
As discussed before, it is difficult to compare the dose-effect curves of Heparin and Argatroban 
in vitro immediately and without any confusion. The first reason for this is that the unit for the 
measurement of the dose in Argatroban is mg per ml whereas it is IU per ml for Heparin. But if 
this differenced is neglected and the two dose-effect curves are compared, there is an indication 
that the dose-effect curve of Argatroban is in fact steeper and less predictable than that of 
Heparin. This is unlike what Elg et al. 1998 stated; that the DTIs have wider therapeutic ranges 
and shallower dose-effect curves compared to a traditional anticoagulant like Warfarin. But of 
course there are two important points about this claim, that first of all Heparin is a completely 
different anticoagulant than Warfarin with a different mechanism and interactions and second of 
all, our experiments were made in vitro. Further,  
Therefore, by neglecting the difference of dose units in the comparison, the following 
assumptions could be made for the dose-effect of Argatroban to be steeper and less predictable 
than Heparin in vitro: 
1. Heparin has more interactions and bindings with the in vitro plasma materials than 
Argatroban which makes it less bioavailable and its dose-effect curve shallower. 
2. Argatroban should have more interactions and bindings than Heparin in vivo which 
would make it less bioavailable in vivo than Heparin and its dose effect curve shallower. 
If the argument for the second assumption is valid, the dose-effect curve of Argatroban would be 
shallower than Heparin in vivo which is unlike their comparison in vivo. Despite the fact that 
unlike Heparin, we do not have so much information regarding the interactions of Argatroban in 
vivo the extremely huge difference of the dose effect curves of Argatroban (figure 20) suggests 
that this could be true and Argatroban has more extensive bindings and interactions with the 
plasma materials in vivo. 
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On the other hand, as mentioned before, there is also proof for the interactions of Heparin with 
the plasma proteins, macrophages and the endothelial cells (Hirch et al. 2001). According to 
Edens et al. 2001, certain UFH have high interactions for Vitronectin. Moreover Factor H-related 
Protein 5 does also bind with Heparin (McRae et al. 2005).  
Since the plasma in vitro would still retain its dissolved proteins, there is a fair possibility that 
Heparin interacts with those proteins and other materials more than Argatroban and therefore it 
becomes less bioavailable and its dose-effect curve would be shallower than that of Argatroban. 
 
Conclusion 
To sum up, the in vitro dose-effect curve of Argatroban (where the dose is measured in µg/ml) is 
steeper and less predictable than the dose-effect curve of Heparin (where the dose is measured in 
IU/ml) within doses and clotting time values that are clinically relevant.  
However, the in vivo data indicates a better dose-response relationship for Argatroban. 
According to figure 20, Argatroban dose levels between 8 and 20 µg/ml plasma give clinically 
relevant increases in the clotting time. 
Therefore Heparin has a better dose-effect curve compared to Argatroban in vitro while on the 
other hand Argatroban has a better dose-effect curve than Heparin in vivo. Since this indicates 
that there are large differences between the dose-effect curves of Argatroban and Heparin in vivo 
and in vitro, the results of our experiments cannot be a good indicator for studying and 
comparing the effects of Argatroban to Heparin.  
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Appendices 
  
Coagulation factors 
 
Factor Trivial Name(s) Pathway Characteristic 
Prekallikrein 
(PK) Fletcher factor Intrinsic 
Functions with HMWK and 
factor XII 
High molecular 
weight 
kininogen 
(HMWK) 
contact activation cofactor; 
Fitzgerald, Flaujeac 
Williams factor 
Intrinsic 
Co-factor in kallikrein and factor 
XII activation, necessary in factor 
XIIa activation of XI, precursor 
for bradykinin (a potent 
vasodilator and inducer of 
smooth muscle contraction 
I Fibrinogen Both  
II Prothrombin Both Contains N-term. gla segment 
III Tissue Factor Extrinsic  
IV Calcium Both  
V Proaccelerin, labile factor, accelerator (Ac-) globulin Both Protein cofactor 
VI (same as Va) Accelerin Both This is Va, redundant to Factor V 
VII 
Proconvertin, serum 
prothrombin conversion 
accelerator (SPCA), 
cothromboplastin 
Extrinsic Endopeptidase with gla residues 
VIII 
Antihemophiliac factor A, 
antihemophilic globulin 
(AHG) 
Intrinsic Protein cofactor 
IX Christmas Factor, Intrinsic Endopeptidase with gla residues 
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antihemophilic factor 
B,plasma thromboplastin 
component (PTC) 
X Stuart-Prower Factor Both Endopeptidase with gla residues 
XI Plasma thromboplastin antecedent (PTA) Intrinsic Endopeptidase 
XII Hageman Factor Intrinsic Endopeptidase 
XIII 
Protransglutaminase, fibrin 
stabilizing factor (FSF), 
fibrinoligase 
Both Transpeptidase 
Table 7: primary factors involved in the coagulation cascade [3]
 
The table contains information about the trivial name of the coagulation factors, their involvement pathway and their 
characteristics. 
 
 
Zymogens of Serine 
Proteases Activities  
Factor XII  binds to exposed collagen at site of vessel wall injury, activated by high-MW kininogen and kallikrein  
Factor XI  activated by factor XIIa  
Factor IX  activated by factor XIa in presence of Ca2+  
Factor VII  activated by thrombin in presence of Ca2+  
Factor X  activated on surface of activated platelets by tenase complex and by factor VIIa in presence of tissue factor and Ca2+  
Factor II  activated on surface of activated platelets by prothrombinase complex  
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Cofactors  Activities  
Factor VIII  activated by thrombin; factor VIIIa is a cofactor in the activation of factor X by factor IXa  
Factor V  activated by thrombin; factor Va is a cofactor in the activation of prothrombin by factor Xa  
Factor III (tissue factor)  a subendothelial cell-surface glycoprotein that acts as a cofactor for factor VII  
Fibrinogen  Activity  
Factor I  cleaved by thrombin to form fibrin clot  
Transglutaminase  Activity  
Factor XIII  activated by thrombin in presence of Ca
2+; stabilizes fibrin clot by 
covalent cross-linking  
Regulatory/Other 
Proteins  Activities  
von Willebrand factor  associated with subendothelial connective tissue; serves as a bridge between platelet glycoprotein GPIb/IX and collagen  
Protein C  activated to protein Ca by thrombin bound to thrombomodulin; then degrades factors VIIIa and Va  
Protein S  acts as a cofactor of protein C; both proteins contain gla residues  
Thrombomodulin  protein on the surface of endothelial cells; binds thrombin, which then activates protein C  
Antithrombin III  
most important coagulation inhibitor, controls activities of 
thrombin, and factors IXa, Xa, XIa and XIIa  
Table 8: functional classification of coagulation factors [3] 
In the table the coagulation factors are categorized according to their function or characteristics, moreover the activity of each of 
the coagulation factor and their role in the coagulation process is presented.  
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Preparation of the plasma  
 
With the help of a lab technician at the laboratory a sample of blood was taken from one of the 
members of our group. The taken blood was transferred into 5 ml plastic tubes with 0.5 ml of citrate 
at each of the tubes and the plastic tube was shaken so that the citrate would be distributed evenly in 
the blood sample in order to avoid clotting. The samples which were totally in 10 plastic tubes were 
centrifuged at 3000 g for 15 minutes at 10 °C. The plasma being the pale brown/yellow supernatant 
above the sample in the plastic tubes was separated using pipettes and transferred to new plastic 
tubes. Plasma tubes which are not going to be used are left inside the freezer for later use. 
 
Protocols for the first experiment 
 
Equipments 
1) Ca2+ with 0.025 M 
2) Platelin 
3) Plasma 
4) Glass and plastic tubes 
5) Water bath at 37 °C 
6) Micro-pipettes with tips 
7) Stopwatch 
8) Saline solution 
 
Procedure 
1. Prepare a water bath at 37 °C. 
2. Pour some of the 0.025 M Ca2+ inside a glass tube and let it inside the water bath for at 
least 10 minutes. 
3. Leave all the glass tubes inside the water bath for at least 3 minutes before use. 
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4. Pour 100 µl of plasma inside a glass tube inside the water bath using a micropipette. 
5. Mix 100 µl of platelin with the plasma inside the glass tube and start the stopwatch. 
6. Finally add 10 µl of the saline solution inside the glass tube. 
7. After approximately 6 minutes add 100 µl of Ca2+ inside the glass tube and start the 
stopwatch again.  
8. Hold the glass tube in your hand while it is still inside the water bath and mix it through 
by tilting it inside the water. 
9. Bring glass tube out every couple of seconds and tilt in order to check for the clot. 
10. As soon as a clot which looks like a white thread is detected stop the stopwatch. 
11. Write the time it took for the clot to appear since the addition of Ca2+. 
12. Repeat 1-11 for a couple of times in order to become familiar with the assay and have an 
accurate value for the standard clotting time. 
13. Repeat 1-11 every time a new experiment is began in order to check for the quality of the 
plasma and update your value of reference clotting time. 
 
Variables 
Dependent variables: 
• Reference clotting time 
Controlled variables: 
• Volume of Ca2+ = Volume of plasma = Volume of platelin = 100 µl and the volume of saline = 10 µl 
• The plasma 
• Temperature of the solution in the glass tube = 37 °C 
• Total volume of the solution = 310 µl 
• Time before the addition of Ca2+ = about 6 minutes  
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Protocols for the second experiment 
 
Equipments 
1) Ca2+ with 0.025 M 
2) Ca2+ with 0.250 M 
3) Platelin 
4) Plasma 
5) Glass and plastic tubes 
6) Water bath at 37 °C 
7) Micro-pipettes with tips 
8) Stopwatch 
9) Saline solution 
10) Marker 
 
Procedures and calculations 
Solution preparation 
1. Prepare 9 different plastic tubes and place them in a tube set. 
2. Mark the tubes using a marker from 2 to 10. 
3. Using a micropipette extract 360 µl of 0.025 M Ca2+ and add it to the tube no. 2 and add 
40 µl less to every of the next tube until 40 µl of 0.025 M Ca2+ is added to the tube no. 10. 
4. Using a micropipette extract 40 µl of the saline solution and add it to the tube no.2 and 
add 40 µl more to every of the next tube until 360 µl of saline is added to tube no. 10. 
5. Mix the solution in every plastic tube thoroughly. 
6. Repeat 1-5 with 8 new plastic tubes marked from 11 to 18 using the 0.250 M Ca2+. 
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Measurement of the clotting time 
1. Prepare a water bath at 37 °C. 
2. Leave all the plastic tubes prepared before inside the water bath for at least 10 minutes. 
3. Take a set of 17 glass tubes and mark them using a marker from 2A to 18A. 
4. Take another set of 17 glass tubes and mark them using a marker from 2B to 18B. 
5. Leave all the glass tubes inside the water bath for at least 3 minutes before use. 
6. Pour 100 µl of plasma inside the glass tube 2A in the water bath using a micropipette. 
7. Mix 100 µl of platelin with the plasma inside the glass tube 2A and start the stopwatch. 
8. Finally add 10 µl of the saline solution inside the glass tube 2A. 
9. After approximately 6 minutes add 100 µl of Ca2+ inside the plastic tube 2 and start the 
stopwatch again.  
10. Hold the glass tube in your hand while it is still inside the water bath and mix it through 
by tilting it inside the water. 
11. Bring glass tube out every couple of seconds and tilt in order to check for the clot. 
12. As soon as a clot which looks like a white thread is detected stop the stopwatch. 
13. Write the time it took for the clot to appear since the addition of Ca2+, if no clot appeared 
until after 3 minutes stop the stopwatch and write more than 3 minutes. 
14. Repeat 6-13 for the next glass tubes 3A to 18A by adding the corresponding Ca2+ solution. 
15. Repeat 6-14 for the set B in order to have a better determination of the clotting time for 
each concentration of Ca2+. 
 
Solution preparation 
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Volume of Ca2+ solution used = 100 µl 
Total volume of solution = 310 µl  
From 1 to 10, concentration of Ca2+ solution = 0.025 M 
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1) Ca2+ dilution = 1.0 
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9) Ca2+ dilution = 0.2 
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From 11 to 18, concentration of Ca2+ solution = 0.250 M 
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16) Ca2+ dilution = 0.4 
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Variables 
Measurement of the clotting time 
Independent variables: 
• Ratio of the Ca2+ (both 0.25 M and 0.025 M) to saline volume: 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 
0.3, 0.2 and 0.1 ([Ca2+]) 
Dependent variables: 
• Clotting time 
Controlled variables: 
• Volume of plasma = Volume of platelin = 100 µl  
• The plasma 
• Temperature of the solution in the glass tube = 37 °C 
• Total volume of the solution = 310 µl 
• Time before the addition of Ca2+ = about 6 minutes 
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Protocols for the third experiment 
 
Equipments 
1) Ca2+ with 0.025 M 
2) Platelin 
3) Plasma 
4) Glass and plastic tubes 
5) Water bath at 37 °C 
6) Micro-pipettes with tips 
7) Stopwatch 
8) Saline solution 
9) Marker 
 
Procedures 
Solution preparation 
1. Prepare 9 different plastic tubes and place them in a tube set. 
2. Mark the tubes using a marker from 2 to 10. 
3. Using a micropipette extract 360 µl of plasma and add it to the tube no. 2 and add 40 µl 
less to every of the next tube until 40 µl of plasma is added to the tube no. 10. 
4. Using a micropipette extract 40 µl of the saline solution and add it to the tube no.2 and 
add 40 µl more to every of the next tube until 360 µl of saline is added to tube no. 10. 
5. Mix the solution in every plastic tube thoroughly. 
 
Measurement of the clotting time 
1. Prepare a water bath at 37 °C. 
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2. Pour the solution of 0.025 M Ca2+ inside a glass tube and let it in the water bath for at 
least 10 minutes. 
3. Take a set of 9 glass tubes and mark them using a marker from 2A to 10A. 
4. Take another set of 9 glass tubes and mark them using a marker from 2B to 10B. 
5. Leave all the glass tubes inside the water bath for at least 3 minutes before use. 
6. Pour 100 µl of the plasma solution no. 2 inside the glass tube 2A in the water bath using a 
micropipette. 
7. Mix 100 µl of platelin with the plasma inside the glass tube 2A and start the stopwatch. 
8. Finally add 10 µl of the saline solution inside the glass tube 2A. 
9. After approximately 6 minutes add 100 µl of Ca2+ and start the stopwatch again.  
10. Hold the glass tube in your hand while it is still inside the water bath and mix it through 
by tilting it inside the water. 
11. Bring glass tube out every couple of seconds and tilt in order to check for the clot. 
12. As soon as a clot which looks like a white thread is detected stop the stopwatch. 
13. Write the time it took for the clot to appear since the addition of Ca2+, if no clot appeared 
until after 3 minutes stop the stopwatch and write more than 3 minutes. 
14. Repeat 6-13 for the next glass tubes 3A to 10A by adding the corresponding plasma solution. 
15. Repeat 6-14 for the set B in order to have a better determination of the clotting time for 
each dilution of plasma. 
 
Variables 
Measurement of the clotting time 
Independent variables: 
• Ratio of the plasma to saline volume: 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2 and 0.1 
Dependent variables: 
• Clotting time 
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Controlled variables: 
• Volume of Ca2+ = Volume of platelin = 100 µl  
• The plasma 
• Temperature of the solution in the glass tube = 37 °C 
• Total volume of the solution = 310 µl 
• Time before the addition of Ca2+ = about 6 minutes 
 
Protocols for the fourth experiment 
 
Equipments 
1) Ca2+ with 0.025 M 
2) 100 IU/ml unfractioned Heparin 
3) Platelin 
4) Plasma 
5) Glass and plastic tubes 
6) Water bath at 37 °C 
7) Micro-pipettes with tips 
8) Stopwatch 
9) Saline solution 
10) Marker 
 
Procedures and calculations 
Solution preparation 
1. Prepare 10 different plastic tubes and place them in a tube set. 
2. Mark the tubes using a marker from 1 to 10. 
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3. Using a micropipette extract 1000 µl of Heparin and add it to the tube no. 1, 500 µl to 2, 250 
µl to 3, 125 µl to 7, 62.5 µl to 9 and 31.5 to 10. 
4. Using a micropipette extract 217 µl of Heparin and add it to tube no. 4, 186 µl to 5, 155 
µl to 6 and 95 µl to 8. 
5. Fill saline to all of the tubes so that the overall volume of the solution in each becomes 1000 µl 
6. Mix the solution in every plastic tube thoroughly. 
 
Measurement of the clotting time 
1. Prepare a water bath at 37 °C. 
2. Pour the solution of 0.025 M Ca2+ inside a glass tube and let it in the water bath for at 
least 10 minutes. 
3. Take a set of 10 glass tubes and mark them using a marker from 1A to 10A. 
4. Take another set of 10 glass tubes and mark them using a marker from 1B to 10B. 
5. Leave all the glass tubes inside the water bath for at least 3 minutes before use. 
6. Pour 100 µl of the plasma solution inside the glass tube 1A in the water bath using a 
micropipette. 
7. Mix 10 µl of the Heparin solution from glass no. 1. 
8. Finally add 100 µl of the platelin and start the stopwatch. 
9. After approximately 6 minutes add 100 µl of Ca2+ and start the stopwatch again.  
10. Hold the glass tube in your hand while it is still inside the water bath and mix it through 
by tilting it inside the water. 
11. Bring glass tube out every couple of seconds and tilt in order to check for the clot. 
12. As soon as a clot which looks like a white thread is detected stop the stopwatch. 
13. Write the time it took for the clot to appear since the addition of Ca2+, if no clot appeared 
until after 30 minutes stop the stopwatch and write more than 30 minutes. 
14. Repeat 6-13 for the next glass tubes 2A to 10A by adding the corresponding Heparin solution. 
15. Repeat 6-14 for the set B in order to have a better determination of the clotting time for 
each dilution of Heparin. 
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Measurement of the clotting time 
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Volume of Heparin solution used = 10 µl 
Total volume of solution = 310 µl 
Dose of Heparin = 100 IU/ml 
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Variables 
Measurement of the clotting time 
Independent variables:  
• Ratio of the Heparin to saline volume: 1, 0.5, 0.25, 0.217, 0.186, 0.155, 0.125, 0.095, 
0.0625 and 0.0313 (Dose of Heparin) 
Dependent variables: 
• Clotting time 
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Controlled variables: 
• Volume of plasma = Volume of platelin = Volume of Ca2+ = 100 µl  
• The plasma 
• Temperature of the solution in the glass tube = 37 °C 
• Total volume of the solution = 310 µl 
• Time before the addition of Ca2+ = about 6 minutes 
 
Protocols for the fifth experiment 
 
Equipments 
1) Ca2+ with 0.025 M 
2) 100 mg/ml Argatroban 
3) Platelin 
4) Plasma 
5) Glass and plastic tubes 
6) Water bath at 37 °C 
7) Micro-pipettes with tips 
8) Stopwatch 
9) Saline solution 
10) Marker 
 
Procedures and calculations 
Solution preparation 
1. Prepare 20 different plastic tubes and place them in a tube set. 
2. Mark the tubes using a marker from 1 to 20. 
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3. Using a micropipette and from the 100 mg/ml bottle extract 465 µl of Argatroban and 
add it to the tube no. 1, 220 µl to 3, 155 µl to 4, 60 µl to 5, 20 µl to 7 and 10 to 8. 
4. Fill saline to all of the tubes so that the overall volume of the solution in each 
becomes 1000 µl. 
5. Mix the solution in every of these 6 plastic tube thoroughly. 
6. Extract 735 µl from tube no. 1 and add to no. 2. 
7. Repeat 4-5 for plastic tube no. 2. 
8. Extract 515 µl from tube no. 5 and add it to tube no. 6 and also 135 µl to no. 9. 
9. Repeat 4-5 for plastic tubes no. 5 and 6. 
10. Using a micropipette and from tube no. 8 extract 500 µl and add it to the tube no. 10, 
200 µl to 11and 100 to 12. 
11. Repeat 4-5 for plastic tubes no. 10, 11 and 12. 
12. Extract 40 µl from tube no. 7 and add to no. 13. 
13. Repeat 4-5 for plastic tube no. 13. 
14. Extract 500 µl from tube no. 12 and add to no. 14. 
15. Repeat 4-5 for plastic tube no. 14. 
16. Extract 500 µl from tube no. 13 and add to no. 15. 
17. Repeat 4-5 for plastic tube no. 15. 
18. Extract 500 µl from tube no. 15 and add to no. 16. 
19. Repeat 4-5 for plastic tube no. 16. 
20. Extract 100 µl from tube no. 12 and add to no. 17. 
21. Repeat 4-5 for plastic tube no. 17. 
22. Extract 500 µl from tube no. 17 and add to no. 18. 
23. Repeat 4-5 for plastic tube no. 18. 
24. Extract 500 µl from tube no. 18 and add to no. 19. 
25. Repeat 4-5 for plastic tube no. 19. 
26. Extract 500 µl from tube no. 19 and add to no. 20. 
27. Repeat 4-5 for plastic tube no. 20.  
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Measurement of the clotting time 
1. Prepare a water bath at 37 °C. 
2. Pour the solution of 0.025 M Ca2+ inside a glass tube and let it in the water bath for 
at least 10 minutes. 
3. Take a set of 20 glass tubes and mark them using a marker from 1A to 20A. 
4. Take another set of 20 glass tubes and mark them using a marker from 1B to 20B. 
5. Leave all the glass tubes inside the water bath for at least 3 minutes before use. 
6. Pour 100 µl of the plasma solution inside the glass tube 1A in the water bath using a 
micropipette. 
7. Mix 10 µl of the Argatroban solution from glass no. 1. 
8. Finally add 100 µl of the platelin and start the stopwatch. 
9. After approximately 6 minutes add 100 µl of Ca2+ and start the stopwatch again.  
10. Hold the glass tube in your hand while it is still inside the water bath and mix it 
through by tilting it inside the water. 
11. Bring glass tube out every couple of seconds and tilt in order to check for the clot. 
12. As soon as a clot which looks like a white thread is detected stop the stopwatch. 
13. Write the time it took for the clot to appear since the addition of Ca2+, if no clot 
appeared until after 30 minutes stop the stopwatch and write more than 30 minutes. 
14. Repeat 6-13 for the next glass tubes 2A to 10A by adding the corresponding 
Argatroban solution. 
15. Repeat 6-14 for the set B in order to have a better determination of the clotting time 
for each dilution of Heparin.  
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Measurement of the clotting time 
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Volume of Argatroban solution used = 10 µl 
Total volume of solution = 310 µl 
 
1)  
Argatroban solution used = 100 mg/ml 
Volume of Argatroban = 465 µl 
Volume of saline = 535 µl 
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2)  
Argatroban solution used = 46.5000 mg/ml 
Volume of Argatroban = 735 µl 
Volume of saline = 265 µl 
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3)  
Argatroban solution used = 100 mg/ml 
Volume of Argatroban = 220 µl 
Volume of saline = 780 µl 
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4)  
Argatroban solution used = 100 mg/ml 
Volume of Argatroban = 155 µl 
Volume of saline = 845 µl 
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5)  
Argatroban solution used = 100 mg/ml 
Volume of Argatroban = 60 µl 
Volume of saline = 940 µl 
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6)  
Argatroban solution used = 6.00000 mg/ml 
Volume of Argatroban = 515 µl 
Volume of saline = 485 µl 
& $ !#! 
*'*(
,*( / *'*(
 -	




$JK>  )	
.


$	K> 
& $ !$! 
'
(
)'
(
 )	
.


$	K>  
	
..-,$	K> 
7)  
Argatroban solution used = 100 mg/ml 
Volume of Argatroban = 20 µl 
Volume of saline = 980 µl 
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8)  
Argatroban solution used = 100 mg/ml 
Volume of Argatroban = 10 µl 
Volume of saline = 990 µl 
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9)  
Argatroban solution used = 6.00000 mg/ml 
Volume of Argatroban = 135 µl 
Volume of saline = 865 µl 
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10)  
Argatroban solution used = '	
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Volume of Argatroban = 500 µl 
Volume of saline = 500 µl 
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11)  
Argatroban solution used = '	
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Volume of Argatroban = 200 µl 
Volume of saline = 800 µl 
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12)  
Argatroban solution used = '	




$	K> 
Volume of Argatroban = 100 µl 
Volume of saline = 900 µl 
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13)  
Argatroban solution used = 	
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Volume of Argatroban = 40 µl 
Volume of saline = 960 µl 
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14)  
Argatroban solution used = 
	'



$	K> 
Volume of Argatroban = 500 µl 
Volume of saline = 500 µl 
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15)  
Argatroban solution used = 
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Volume of Argatroban = 500 µl 
Volume of saline = 500 µl 
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16)  
Argatroban solution used = 
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Volume of Argatroban = 500 µl 
Volume of saline = 500 µl 
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17)  
Argatroban solution used = 
	'
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Volume of Argatroban = 100 µl 
Volume of saline = 900 µl 
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18)  
Argatroban solution used = 
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Volume of Argatroban = 500 µl 
Volume of saline = 500 µl 
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19)  
Argatroban solution used = 
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Volume of Argatroban = 500 µl 
Volume of saline = 500 µl 
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20)  
Argatroban solution used = 
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Volume of Argatroban = 500 µl 
Volume of saline = 500 µl 
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Variables 
Measurement of the clotting time 
Independent variables: 
• Dose of Argatroban: 0.00004 mg/ml, 0.00008 mg/ml, 0.00016 mg/ml, 0.00032 mg/ml, 
0.00065 mg/ml, 0.00129 mg/ml, 0.00161 mg/ml, 0.00258 mg/ml, 0.00323 mg/ml, 
0.00645 mg/ml, 0.01613 mg/ml, 0.02613 mg/ml, 0.03226 mg/ml, 0.06452 mg/ml, 
0.09968 mg/ml, 0.19355 mg/ml, 0.50000 mg/ml, 0.70968 mg/ml, 1.10250 mg/ml and 
1.50000 mg/ml 
Dependent variables: 
• Clotting time 
Controlled variables: 
• Volume of plasma = Volume of platelin = Volume of Ca2+ = 100 µl  
• The plasma 
• Temperature of the solution in the glass tube = 37 °C 
• Total volume of the solution = 310 µl 
• Time before the addition of Ca2+ = about 6 minutes 
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